Studies on common genital HPV types, HPV variants and HPV integration in the development of cervical carcinoma by Donaldson, Yvonne K.
STUDIES ON COMMON GENITAL HPV TYPES, HPV VARIANTS
AND HPV INTEGRATION IN THE DEVELOPMENT OF CERVICAL
CARCINOMA.
Yvonne K Donaldson
presented for the degree of Doctor of Philosophy
University of Edinburgh
1992
This thesis and all the experimental results presented herein, unless stated






I am indebted to my supervisors Drs Mark Arends and Edward Duvall
for their constmctive advice, encouragement and unlimited enthusiasm
during my period of study. I wish to express my gratitude to Professor
C.C. Bird for making it possible for me to undertake this study and to Dr
Andrew Wyllie for advice. My thanks also go to Robert Morris, Dave
Cossar, Scott Cunningham, Craig Walker and Francis Rae for technical
assistance; Professor Busuttil for autopsy specimens; Drs G Smart and J
Livingstone for CIN biopsies; Paul Bishop for clinical specimens; and
Professors H. zur Hausen and L Gissmann and Dr J DiPaolo for the
generous gift of HPV plasmids. Outwith the department my special
thanks go to my parents and also to Edward Hurst and Suzanne Munday




There has been considerable epidemiological and experimental evidence
to support a role for human papillomavirus (HPV) in the development of
cervical cancer, however the precise contribution of HPV remains
controversial. Variation in prevalence of HPV types in cervical lesions has
been found and there have been reports of a high prevalence of HPV in
normal tissue. These variable findings have been attributed to several
factors including the different detection and cervical sampling techniques
used. In this study, a polymerase chain reaction (PCR) based assay for the
detection of the common genital HPV types 6b, 11, 16, 18 and 33 was
designed and optimised for both sensitivity and specificity. The assay was
applied to 24 normal control cases, 20 cases each of cervical intraepithelial
neoplasia (CIN) 1, CIN 2, CIN 3, 26 cases of squamous carcinoma, 16
cases of adenocarcinoma and 4 cases of mixed adenosquamous carcinoma.
HPV DNA was found in 25% of CIN 1 cases, 60% of both CIN 2 and
CIN 3 cases and in 80% of cervical carcinomas. A novel finding was that
no HPV DNA was detected in the normal control cases. No HPV 6b or 33
DNA was found and HPV 11 was detected in only 5% of CIN 1 cases.
HPV 16 and HPV 18 were seen with increasing frequency through the
spectmm of cervical disease. The results of these assays support a role for
HPV 16 and 18 in neoplastic progression and emphasise the biological
similarity of CIN 2 and CIN 3 and their divergence from CIN 1.
The prevalence of HPV 16 and HPV 18 in cervical neoplasms was
compared. HPV 16 was found in more squamous carcinomas (58%) than
HPV 18 (23%), whereas in adenocarcinomas - which have a poorer
prognosis than squamous carcinomas - both HPV types showed an equal
prevalence (44%). Thus, in terms of cancer cell differentiation HPV 16
appeared to confer a better prognosis than HPV 18. The frequency of
HPV 16 in all cancers and CINs gave a CANCER/CIN prevalence ratio
of 1.4 (54%/38%) as compared to one of 3.75 (30%/8%) for HPV 18 - a
2.6 fold difference - indicating either a greater risk of, or more rapid
progression to malignancy associated with HPV 18. These findings
suggest that HPV 18 is more aggressive than HPV 16.
While HPV types 16 and 18 appear to contribute to the neoplastic process
not all cases of HPV infection will progress to invasive carcinoma
indicating the likely involvement of additional events or factors. It has
been suggested that HPV variants with sequence alterations to the
upstream regulatory region (URR) may contribute to the neoplastic
process through an altered pattern of gene expression. Little is known of
their prevalence in cervical lesions. In this study a PCR assay was
designed specifically to detect large scale sequence alterations in the
HPV 16 and 18 URR. The assay was applied to 24 cases of CIN (20 HPV
16, 4 HPV 18) and 34 cases of carcinoma (22 HPV 16, 11 HPV 18, 1
HPV 16 and HPV 18). No URR alterations were found indicating that
HPV variants are not widespread in cervical lesions.
HPV DNA of types 16 and 18 has been found integrated in a
monoclonal pattern into the host genome in a high proportion of cervical
carcinomas and cell lines derived from them. It is thought that this event
may disrupt the replicative pattern of viral gene expression and effect
sustained or increased transcription of the transforming E6 and E7 genes,
contributing to the neoplastic process. However it is unclear at which
stage in cervical carcinogenesis this event occurs. Here, a PCR based
assay was designed to determine the physical state of HPV 16 DNA. This
assay differs from previously described methods in that it was designed
to be applicable to small clinical samples such as punch biopsies of CIN.
The assay has been successfully applied to cloned HPV plasmid DNA
and is now ready to be used to determine the proportion of CIN 2, CIN 3





CHAPTER 1: INTRODUCTION 1
1.1 Cervical cancer and precc *sor lesions 2
1.2 Aetiology of CIN and cervical c ancer 5
1.3 The Biology of HPV 7
1.3.1 Virion properties and Classification 7
1.3.2 Papillomavirus infection 8
1.3.3 Genome Organization and Function 8
1.4 Papillomavirus Transformation 17
1.5 Mechanism of HPV Transforming Activity 20
1.6 Regulation of HPV Gene Expression 21
1.6.1 Organisation of the URR 21
1.6.2 Regulation by E2 22
1.6.3 Regulation by Cellular Factors 25
1.7 Alterations in the Viral Upstream Regulatory Region (URR) 27
1.8 Physical State of HPV DNA in Cervical Tumours 29
1.8.1 Effects of integration on the viral genome 30
1.8.2 Effects of integration on the cell genome 31
1.9 HPV and Cellular Oncogenes 31
1.10 Additional Risk Factors for Cervical Neoplasia 32
1.11 A Multistage Model for Cervical Carcinogenesis 33
1.12 Aims 37
CHAPTER 2: MATERIALS AND METHODS 38
2.1 Clinical Material 39
2.2 Histopathological Examination 39
2.3 Oligonucleotide Selection and Synthesis 40
2.4 Preparation of Materials for PCR 40
2.5 Polymerase Chain Reaction 42
2.6 Procedures to Minimise the Risk of Contamination 42
2.7 Amplification of Reference Gene 43
2.8 Dot Blot Hybridisation 43
2.9 Restriction Enzyme Mapping 45
2.10 Anchor PCR 45




3.2.1 Design of oligonucleotides for the detection assay 50
3.2.2 Optimization of condition for the detection assay 56
3.2.3 Validation of the detection assay for HPV type 58
specificity
3.2.4 Validation of the detection assay for sensitivity 60
3.3 Discussion 65
CHAPTER 4: DETECTION OF HPV IN CERVICAL 69
NEOPLASIA
4.1 Introduction 70
4.2 Cases studied ^0
4.3 Results 71
4.4 Discussion 76
CHAPTER 5: DETECTION OF LARGE SCALE 90
SEQUENCE ALTERATIONS IN THE HPV URR
5.1 Introduction 91
5.2 Assay design 94
5.3 Results 98
5.4 Discussion 105
CHAPTER 6: DESIGN OF A PCR-BASED ASSAY TO 109
DETERMINE THE PHYSICAL STATE OF HPV DNA
IN CERVICAL LESIONS
6.1 Introduction 110
6.2 Assay design 112
6.2.1 PCR analysis 112
6.2.2 Anchor-PCR analysis 114
6.2.3 Primer Design 118
6.2.4 Optimization of conditions for initial PCR 118
6.2.5 Selection of restriction enzyme sites 121
6.3 Results 121
6.4 Discussion 123




Cervical cancer is the largest single cause of cancer related deaths among
women in developing countries and worldwide is second only to breast
cancer with an estimated 459,000 new cases worldwide each year
(Stanley et al., 1987). Cervical neoplasia is a multistage disease which
has a precursor of malignancy recognised morphologically as cervical
intraepithelial neoplasia (CIN). In countries such as Denmark, Finland
and parts of Scotland, systematic cytological screening programs aimed
at detecting and treating CIN have been effective in reducing the
incidence ofmortality from cervical cancer (Report of the Intercollegiate
working party on cervical screening, 1987). However, UK statistics
show an increase in the incidence of both cervical cancer and CIN,
particularly in young women (Scottish cytology statistics, 1986; Report
of the Intercollegiate working party on cervical screening, 1987; Cancer
registration statistics, Scotland, 1990).
1.1 Cervical Cancer and precursor lesions
Cervical cancer is heterogeneous in its patterns of differentiation and can
be divided histopathologically into squamous carcinoma, adenocarcinoma
and adenosquamous carcinoma. Squamous carcinomas are defined as
tumours composed of cells resembling those of the squamous epithelium
whereas, adenocarcinomas show glandular differentiation and are often
recognised by their capacity to secrete mucin. Adenosquamous
carcinomas may represent the centre ground of a spectrum of
bipotentiality as they contain both squamous and adenocarcinomatous
elements and behave biologically in a very similar manner to squamous
carcinoma with mucin production (Buckley and Fox, 1989). Squamous
carcinomas have been more extensively studied than adenocarcinomas
and adenosquamous carcinomas probably owing to the fact that this type
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constitutes the majority of all cervical cancers.
Squamous carcinoma has a precursor stage known as CIN which
represents a spectrum of disorder in the epithelium. CIN can be
categorised into arbitrary grades one, two or three on the basis of whether
disordered cells comprise one third, two thirds or the entire thickness of
the epithelium respectively (figure 1.1). Invasive cancer develops from
CIN when disordered cells breach the underlying basement membrane
invading the stroma.
Evidence supporting this sequence of events has come from
epidemiological studies which have found identical risk factors for CIN
and invasive lesions (Rotkin, 1973; Vessey et al., 1983; Greenberg et al.,
1985) and prevalence studies which have found the age distribution of
the different lesions to be consistent with multistage progression in that
the more severe grades of CIN tend to be found in older women. A
retrospective study of untreated patients with precancerous lesions of the
cervix found that in 27% of cases, invasive cancer developed within ten
years (Peterson, 1956). A similar study found that 19% of women with
CIN lesions may develop invasive cancer if untreated for two years or
more (Kinlen and Spriggs, 1978). More recently Nasiell et al (1983)
found that 30% of 894 women with CIN 2 lesions developed carcinoma
in situ (CIN 3) within 50 to 78 months.
Despite the existence of a spectrum of change, development of invasive
carcinoma may not necessarily involve sequential progression through a
stable CIN 1, 2 and 3 stage. Possible pathways may involve progression
to invasive cancer from normal epithelium via a stable CIN 2 or CIN 3
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Figure 1.1
Diagramatic representation of the spectrum of change in the cervical
epithelium recognised morphologically as cervical intraepithelial
neoplasia (CIN). Increasing severity of CIN is characterised by a
progressive increase in the number of disordered cells until the full
thickness of the epithelium is involved. Data modified from Ferenczy and
Winkler (1987).
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stage, or from normal epithelium via a CIN 1 stage only or even directly
from normal epithelium (Reid and Fu, 1986). Furthermore, there are
many cases of CIN which do not progress in the lifetime of the woman,
some persist and others regress. While the likelihood for regression
decreases with increasing severity of CIN there is no way of predicting
the clinical outcome of any individual lesion.
Adenocarcinoma in situ (AIS) and glandular atypia have been proposed
as precursor lesions of glandular carcinoma on the basis of their
morphological features - which are similar to adenocarcinoma without
stromal invasion - and also the age distribution of the lesions which is in
keeping with multistage progression (Wells and Brown, 1986). However,
there has been no direct proof that glandular atypia will progress to AIS
and then finally to invasive cancer. In addition, it is possible that
adenocarcinoma may develop from CIN and that AIS may progress to
squamous carcinoma.
1.2 Aetiology of CIN and Cervical Cancer
The epidemiology of both CIN and cervical cancer show a clear
correlation between the disease and sexual behaviour. Several risk factors
have been identified including multiple sexual partners and early age at
first intercourse (Brinton and Fraumeni, 1986; Parazzini et al., 1988),
suggesting an aetiological role for a sexually transmitted infectious agent.
While a number of candidates have been implicated, recent years have
seen the accumulation of considerable evidence supporting a key role for
the genital human papillomaviruses (HPV) in the neoplastic process.
Some of this evidence has been provided by epidemiological and HPV
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prevalence studies which have found HPV DNA in CIN lesions in punch
biopsies and cervical smears and in up to 90% of squamous cervical
cancers (Arends et al., 1990). HPV DNA has also been found by some
investigators in glandular cervical carcinomas and tumours of mixed
differentiation (Tase et al., 1988).
It might be argued that HPV is present in these lesions as a passenger and
that the vims merely has a predilection for infecting CIN. However,
evidence to the contrary comes from the fact that different HPV types
have been found in association with specific lesions. HPV 6 and HPV 11
are found mainly in low grade CIN (CIN1) and warts whereas HPV 16
and HPV 18 are found in higher grade CIN (2-3) and invasive
carcinomas (Gissmann, 1984; Brescia et al., 1986; Pater et al., 1986;
Syrjanen et al., 1987). A comparison of the spectrum of condyloma, CIN,
carcinoma-in-situ (CIS) and invasive carcinoma has shown a progressive
increase in the prevalence of HPV 16 and 18 and a corresponding
decrease in HPV 6 and 11 (Gissmann, 1984). On this basis, HPV types 6
and 11 have been categorised as low risk and HPV types 16 and 18 as
high risk. Furthermore, HPV 18 appears to be associated with glandular
cancers of the cervix and HPV 16 with squamous carcinoma (Wilczynski
et al., 1988; Okagaki et al., 1989; Leminen et al., 1991). HPV 18 may
also be associated with a more aggressive form of cervical cancer than
HPV16 based on the relatively low prevalence of HPV 18 in CIN
compared with cervical cancers (Kurman et al., 1988).
There are over sixty HPV types now identified and several more have
been detected in cervical lesions, albeit less frequently than types 6, 11,
16 and 18. These include HPV types 30, 40, 42, 43, 44 and 58 which are
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associated with CIN and types 31, 33, 35, 39, 45, 51 and 52 which are
associated with both CIN and cervical carcinoma (de Villiers, 1989).
However, there are still some cervical cancers which are negative for
HPV DNA. While these cancers may be genuinely unrelated to HPV
infection it is also possible that they contain HPV DNA at a copy number
that is too low for detection by previously used methods. It is also
possible that these apparently HPV negative carcinomas may contain
HPV types which are yet to be characterized.
1.3 The Biology of HPV
Whilst epidemiological evidence strongly suggests a role for HPV in the
development of cervical carcinoma the precise nature of the involvement
is unclear. The study of HPV biology has contributed to the
understanding of the possible mechanisms by which viral infection may
influence cellular genes and gene products.
1.3.1 Virion Properties and Classification.
The papillomaviruses are members of the Papovaviridae. They are
unenveloped and have cubic capsids which contain closed circular double
stranded DNA of approximately 8kb in length (Pfister, 1987). They are
classified in accordance with the host species they infect and by the
degree of cross hybridisation in the liquid phase. Different PV types have
less than 50% cross hybridisation (Coggin and zur Hausen, 1979),
whereas different subtypes have greater than 50% cross hybridisation but
with different restriction enzyme cleavage patterns. The most extensively
studied of the PVs are the bovine papillomaviruses (BPV) and the human
papillomaviruses (HPV). The different types of HPV can be grouped
according to the sites of their associated lesions (de Villiers, 1989). The
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genital PVs are considered a family as a single family. Other families
include those infecting the skin and those causing fibropapillomas.
1.3.2 Papillomavirus Infection
The PVs infect the squamous epithelium of skin and mucosae producing
proliferations with different growth patterns dependent upon the site of
infection and vims type. Initial infection requires direct physical access to
basal cells such as occurs at local abrasions or at the transformation zone
of the cervical squamocolumnar junction. Subsequent viral replication
appears to be very closely linked and possibly dependent on epithelial cell
differentiation (Bedell et al., 1991). In the lower layers of the squamous
cervical epithelium the early genes which regulate DNA synthesis are
expressed (Pfister, 1987) whereas the expression of capsid proteins and
packaging of viral genomes are limited to the most highly differentiated
upper layers indicating that different stages of the viral life cycle may
require specific factors only provided by sequential differentiated stages of
epithelial tissue. Until recently study of the mechanisms by which
epithelial differentiation could influence papillomavirus replication was
hindered due to inadequate culture methods. The recently developed in
vitro raft culture systems and xenografting techniques may help to
overcome this problem by mimicking the differentiation-specific processes
seen in vivo thus allowing the study of many aspects of the viral life cycle
including actual vims production (Merrick et al., 1992).
1.3.3 Genome Organization and Function
The PVs infecting animals and humans all exhibit a very similar
organization of the genome with at least ten potential open reading frames
(ORFs) all occuring in similar positions on the same DNA strand (Chen et
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al., 1982; Schwarz et al., 1983; Seedorf et al., 1985; Matsukura et al.,
1986) (figure 1.2). The genome can be functionally divided into three
regions: a non coding region commonly termed the upstream regulatory
region (URR) which contains transcriptional control sequences and the
origin of replication, followed by two coding regions; an early coding (E)
region containing genes El - E8 and a late coding region containing
genes LI and L2. The transcription of viral DNA into messenger RNA
(mRNA) includes the formation of both unspliced and spliced mRNA
and more than one protein may derive from the same coding sequence
(Pettersson et al., 1987). Functions have now been assigned to almost all
of the ORFs. This has been achieved primarily by experiments in which
the ORF of interest is deleted, mutated or subcloned and overexpressed
(from a surrogate promoter in the absence of the other ORFs), using
either human or bovine papillomavirus genomes. The assigned functions
of the HPV ORFs are summarised in table 1.3.
The LI and L2 open reading frames
This region contains two large ORFs, LI and L2, which code for viral
structural proteins. LI, the most highly conserved viral gene codes for a
major capsid protein. The L2 ORF codes for a similarly sized but poorly
conserved minor capsid protein (Pilacinski et al., 1984; Rose et al., 1990).
The El open reading frame
The BPV 1 El ORF encodes sequences for two complementation groups
involved in different aspects of viral replication. The 3' R gene portion is
required for early replication events possibly encoding a positive
replication factor required for initial amplification of DNA soon after
infection. Mutation of this region always leads to integration of the virus
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Figure 1.2
Genome organization of BPV 1 (Chen et al, 1982), HPV 6 (Schwarz et
al, 1983) and HPV 16 (Seedorf et al, 1985; Matsukura et al, 1986). The
open bars represent open reading frames (ORFs) for each of the three
potential translation frames. E and L denote early and late region ORFs
respectively. Solid bars indicate the upstream regulatory regions. There is
a translation start codon (ATG) at or near the beginning of almost all the
coding sequences. All ORFs are capable of coding for a polypeptide
















Table of HPV ORF function (see text for details).
ORF Properties
E1 virus replication, episomal maintenance
E2 positive and negative transcriptional control
E4 late function; virus release
E5 membrane protein; transforming function?
E6 transforming gene
E7 transforming gene
L1 major capsid protein
L2 minor capsid protein
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into the host genome. The 5' M gene portion encodes a trans-acting factor
which represses BPV 1 replication (Berg et al., 1986). Interestingly, two
HPV 11 cDNAs with the potential to encode two fusion proteins
incorporating the putative E1M domain have been recovered using
retroviral gene transfer (Rotenberg et al., 1989; Chiang et al., 1991).
Functional analysis suggested that these proteins are both trancriptional
repressors (Chiang et al., 1991).
The E2 open reading frame
E2 is thought to play a key role in the negative and positive control of
viral transcription. Using the BPV 1 model the E2 ORF has been found to
encode at least 3 transcriptional regulatory proteins which all share the
same carboxyl terminal but have different functions: a full length E2 gene
product (E2) transactivates the BPV 1 E6-E7 promoter (Spalholz et al.,
1985) a short C-terminal E2 gene product (E2-C) represses transactivation
by the full length E2 gene product (Lambert et al., 1987a, 1987b; Cripe
et al., 1987); a recently defined E2/E8 fusion protein, is also a
transcriptional repressor (Lambert et al.,1987a ,1989). Proteins
corresponding to these gene products have been identified in BPV 1
transformed cells (Hubbert et al., 1988). The C-terminal region of both
the HPV 16 and HPV 11 E2 ORFs have the coding capacity for a
repressor function similar to BPV 1 E2-C, however the actual protein has
not been identified in infected cells (Cripe et al., 1987; Chin et al., 1988).
Transcriptional regulation by the E2 proteins is mediated by direct
binding to the palindromic sequence ACCN^GGT (E2 binding sites or
E2BS) (Haugen et al., 1987; Spalholz et al., 1987; Androphy et al.,
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1987a; Moskaluk and Bastia, 1988a; McBride et al., 1988) found in all
the known papillomavirus URRs (Dartmann et al., 1986), with the
exception of HPV41, which contains a modification of this sequence
(Hiit et al., 1990). The number and location of the E2 binding sites
differs among vims types. Although there is little homology between PV
E2 proteins, analysis of the alignment of the amino acid sequences of 10
E2 proteins reveals three distinct regions: two partially conserved
domains at the N and C termini of the protein and a hinge region variable
in size and sequence in the middle (Giri and Yaniv, 1988) (figure 1.4).
Mutational analysis has allowed particular functions to be ascribed to the
three domains (Giri and Yaniv, 1988; McBride et al, 1989). The C
terminal domain is responsible for DNA binding and dimerization (Giri
and Yaniv, 1988). C terminal E2 polypeptides synthesized in vitro have
been shown to bind the perfect palindromic sequence ACCGN4CGGT
and with lower affinity the degenerate palindromic sequence
ACCN6GGT (Androphy et al, 1987a; McBride et al, 1988; Hawley-
Nelson et al, 1988; Moskaluk and Bastia, 1988a; 1988b). Interestingly,
the C terminal domain contains motifs capable of forming "leucine
zipper" type structures (O'Shea et al., 1989). Such structures are involved
in dimerization of certain known DNA binding proteins (Landshultz et
al., 1988), however their involvement in E2 dimerization and DNA
binding is yet to be established.
It seems likely that the E2/E8 and E2-C repressors which share a
common C terminal will also share dimerization and DNA binding
functions. Thus these repressor proteins could exert their effect by
competing with E2 for binding sites or also by the formation of
heterodimers between repressor and full length E2 protein (Lambert et
13
Figure 1.4
Computer predicted secondary structure of the full length E2 protein.
Hatched bars represent conserved alpha helices. Two long helices in the
transactivating domain are named A1 and A2. Open bars represent
conserved beta strands. The long beta strand in the transactivating
domain is labelled B. Solid lines indicate sequences of undetermined
structure. The zig-zag line indicates the absence of reliable structural













al., 1987b; Haugen et al., 1988; McBride et al., 1989).
The N terminal consists of 2 negative amphipathic alpha helices and a
small beta strand. Mutational analysis showed the alpha helices to be
essential for transactivation while the beta strand had a less important
effect (Giri and Yaniv, 1988). Negative amphipathic helices are thought
to be directly involved in transcription through protein-protein
interactions with transcription factors and are a common feature among
transactivator proteins (Giniger and Ptashne, 1987). Although binding
affinity of E2 proteins is similar with one or two tandem repeated E2BSs
a minimum of two is required for a functional E2 responsive enhancer
(Gius et al., 1988; Hawley-Nelson et al., 1988; Spalholz et al., 1988). A
recent report has shown that BPV 1 E2 binds to the E2BS as a dimer and
then multimerizes further into a stable protein-DNA complex forming
DNA loops if the palindromes are far apart (Knight et al., 1991). This
looping out could bring distant E2 proteins close to the promoter enabling
them to interact with bound cellular transcription factors.
Although the precise mechanism by which E2 activates transcription is
unknown it is possible that E2 may stabilize the transcription initiation
complex by protein - protein interactions between bound E2 and
transcription machinery such as TFIID and RNA polymerase II.
The E4 open reading frame
The E4 ORF lies within the E2 ORF but in a different reading frame. E4
has been found to be dispensable for many of the early functions and a
late function has been suggested for the gene (Hermonat and Howley,
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1987; Neary et al., 1987). The E4 protein of HPV la has been isolated as
a cytoplasmic protein and has been found to represent up to 30% of total
cellular protein in HPV la induced warts (Doorbar et al., 1986). Another
study has shown that the HPV 16 E4 ORF is expressed as a cytoplasmic
protein in detectable quantities only where episomal replication is
accompanied by late gene expression (Crum et al., 1990). The in vitro
expression of an HPV 16 E1AE4 fusion protein in epithelial cells has
been shown to disrupt cytokeratin organization providing support for a
recent suggestion that E4 may play a role in altering the normal
cytokeratin matrix of an infected cell thus facilitating the release of virus
particles when the cell is shed (Doorbar et al., 1991).
The E5, E6 and E7 open reading frames
The role of the HPV E5 gene in the virus life cycle is not well
understood. Sequence analysis of the HPV 16 genome has revealed that
E5 encodes a small, strongly hydrophobic protein containing 83 amino
acids (Bubb et al., 1988). Recent studies have shown that the HPV 16 E5
gene can interact with the cellular epidermal growth factor receptor to
induce transformation of NEH3T3 cells (Pirn et al., 1992). Furthermore,
studies by Leechanachi et al (1992) have suggested that the E5 gene from
HPV 16 is an oncogene which transforms cells in part through enhancing
signal transduction from growth factors to the nucleus.
The HPV E6 and E7 genes encode the major transforming proteins
(Yutsudo et al., 1988). Their function and mechanism of transforming
activity are discussed later.
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1.4 Papillomavirus Transformation
In the normal stratified squamous epithelium of the cervix, cells stop
dividing as they leave the basal layer and undergo an ordered pattern of
differentiation. The development of CIN in these tissues involves a
disruption of this pattern. One manifestation is an alteration in nuclear
and cytoplasmic maturation initially more obvious in the lower layers of
the epithelium in low grade CIN but, spreading to involve the entire
thickness of the epithelium in high grade CIN. The abnormal cells are
characterized by architectural disorientation, enlarged and irregularly
shaped nuclei and increased and abnormal mitoses. The potential of the
papillomaviruses to alter cellular morphology and growth properties in
such a way has been widely investigated in vitro using transformation
assays and more recently, organotypic raft culture (Merrick et al., 1992).
The high risk HPV types (16 and 18) and low risk HPV types (6 and 11)
differ in their ability to transform both rodent and human cells. HPV
types 16 and 18, but not types 6 and 11, can transform rodent
immortalized cell lines CI27 and NIH3T3 to tumorigenicity (Watts et al.,
1984; Yasumoto et al., 1986; Bedell et al., 1987). In addition, high risk
HPV types 16, 18, 31 and 33 are capable of cooperating with activated
ras oncogene to transform primary rodent kidney epithelial cells - a
feature very rarely seen in the low risk types (Crook et al., 1988; Storey
et al., 1988,1990b).
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However the natural target cell of HPV is not the rodent fibroblast or
epithelial cell but the human keratinocyte. The introduction of HPV DNA
of types 16, 18, 31 and 33 can immortalize human genital keratinocytes
although the resultant cell lines are not tumorigenic (Durst et al., 1987a;
Pirisi et al., 1988; Woodworth et al., 1988, 1989). When such HPV16-
and 18- transfected keratinocytes are cultured on collagen rafts in vitro
they fail to differentiate normally and show histological abnormalities
similar to genital intraepithelial neoplasia in vivo (McCance et al., 1988;
Blanton et al., 1991). Full transformation of HPV-16 immortalized cell
lines requires the introduction of an activated viral Harvey ras gene and
generates cells capable of forming cystic human squamous cell
carcinomas (DiPaolo et al., 1989).
While a low level of transforming activity has been mapped to the E2-E4-
E5 region of both HPV 16 and HPV 18 (Vousden and Jat., 1989; Bedell
et al., 1989), it is the E6 and E7 genes which are primarily involved in
the transformation of cultured cells. In high risk HPV types the E6-E7
subgenomic fragment alone was found to be sufficient to immortalize
rodent cell lines (Bedell et al., 1987; Matlashewski et al., 1987; Vousden
et al., 1988). Furthermore, when E6-E7 immortalized cells were cultured
in a raft system morphological changes occurred similar to those
described above (Hudson et al., 1990). Studies on the independent
immortalizing activity of the HPV 16 E6 and E7 genes in primary rodent
cells found E6 less efficient than E7 (Kanda et al., 1988; Vousden and
Jat, 1989). The E7 sequence of the high risk HPV types can co-operate
with mutated c-Ha-ras to transform primary rodent cells (Storey et al.,
1988; Crook et al., 1988; Chesters et al.,1990). Although the E7 region
of HPV types 16 and 18 is sufficient for the immortalization of primary
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human keratinocytes E6 contributes significantly to the efficiency of the
E7 immortalizing function (Hudson et al., 1990; Halbert et al., 1991).
Further evidence of the importance of E6 and E7 is derived from the
observation that the high risk HPV types 16 and 18 differ in their
capacity to immortalize human keratinocytes, with HPV 18 10-50 fold
more active than HPV 16 (Villa and Schlegel, 1990). This differential
activity has been mapped to the viral URR which controls expression of
the E6 and E7 transforming genes (Romanczuk et al.,1991).
In support of the view that the transforming potential of the HPVs lies
primarily within the E6 and E7 genes^are reports that both human cervical
carcinomas and carcinoma-derived cell lines contain HPV E6 and E7
mRNA and proteins (Smotkin and Wettstein, 1987; Baker et al., 1987;
Seedorf et al., 1987; Androphy et al., 1987b; Shirasawa et al, 1987; Pater
and Pater, 1988).
The HPV E6 and E7 proteins all contain the amino acid motif Cys- X-X-
Cys which mediates zinc binding and is implicated in DNA binding
(Cole and Danos, 1987; Barbosa et al., 1989; Grossman and Laimins,
1989). This motif repeated at regular intervals in BPV 1 E6 protein is
essential for BPV E6 transforming activity (Vousden et al., 1989). Recent
point mutational analyses of the HPV 16 E7 protein have demonstrated
that Cys-X-X-Cys motifs contribute to the transforming potential of E7,
but are not essential to it (Edmonds and Vousden, 1989; Storey et al.,
1990).
Interestingly, DNA sequence analysis predicts the existence of E6*
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mRNAs generated by internal splicing events in the high risk genital
HPV types (Schneider-Gadicke and Schwarz, 1986). However, such
proteins have not yet been identified and no function has been assigned.
1.5 Mechanism of HPV transforming activity
Recent biochemical experiments have shown a mechanism by which the
viral E6 and E7 proteins may affect cellular proliferation. The E7 protein
of oncogenic HPV types shares an amino acid motif with the SV40 large
T antigen, adenovims E1A protein and v- and c-myc oncoproteins. This
motif has been shown to encode the transforming function of SV40 large
T antigen and bind to the protein encoded by retinoblastoma (Rb)
oncosuppressor gene (Figge et al., 1988: Figge and Smith, 1988; Dyson
et al., 1989; Munger et al., 1989). It has been suggested that viral
transforming proteins such as E7 may induce transformation by binding
to the Rb protein and neutralising its growth inhibitory effects thereby
allowing uncontrolled proliferation. In support of the importance of Rb
inactivation in tumours, the Rb gene has been found to be mutated in a
variety of human cancers including sarcomas and breast cancers
(Horowitz et al., 1990).
Similarly, the E6 protein of HPV types 16 and 18 binds to the product of
a second tumor suppressor gene p53 in vitro (Wemess et al., 1990) as
does SV40 large T antigen and adenovims 5 E1B protein (Samow et al.,
1982). However unlike these other oncoproteins, E6 has been shown to
promote the degradation of p53 (Scheffner et al, 1990). This occurs
through the ubiquitin-dependent proteolysis system and is mediated by a
cellular monomelic protein of approximately lOOkDa (Huibregtse et al.,
1991). This discovery would account for the unexpectedly low levels of
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p53 protein found in some of the cervical carcinoma cell lines and HPV-
immortalized squamous epithelial cell lines (Matlashewski et al., 1986).
Thus, HPV 16 and 18 show a striking parallel with SV40 and adenovirus.
All have proteins that bind and inactivate p53 and Rb oncosuppressor
proteins. This conserved dual effect of three DNA tumour viruses may
play an important role in leading to unrestricted cellular proliferation.
Moreover, the abilities of E6 and E7 proteins of different HPV types to
bind the oncosuppressors appear to reflect their oncogenic potentials, in
that HPV types 16 and 18 E6 and E7 proteins bind with greater affinity
than those of HPV 6 or HPV 11 (Munger et al., 1989; Wemess et al.,
1990). In support of this, analysis of a series of HPV positive and
negative human cervical carcinoma cell lines for mutation of the p53 and
Rb genes found that the HPV positive cell lines contained normal Rb
and low levels of wild-type p53, whereas in cell lines lacking HPV DNA
mutations were identified in both genes. Interestingly, the mutations in
p53 were located in highly conserved regions where mutations appear in
a variety of human cancers (Scheffner et al., 1991). These results indicate
the importance of inactivation of the two oncosuppressor proteins Rb and
p53 in the development of cervical cancer.
1.6 Regulation of HPV Gene Expression
1.6.1 Organisation of the URR
The HPV URR is approximately 1000 nucleotides long and lies between
the LI and E6 genes. The 5' end of the URR is rich in poly AT/GT
sequences. Such sequences frequently found in the human genome are
capable of forming Z-DNA structures and enhancing gene expression
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(Hamada et al., 1982, 1984), however their function in the HPV life cycle
is not understood. The 3' region of the URR contains the E6 promoter
(figure 1.5). Between the AT/GT rich region and promoter elements lies a
variety of binding sites and enhancer elements some of which are
responsive to the viral E2 proteins and others which are responsive to
cellular factors.
1.6.2 Regulation by E2
All the PVs sequenced to date have been found to have E2 binding sites
in the URR (Dartmann et al., 1986), however these sites differ
considerably in number, position, E2 responsiveness and conservation of
the palindrome (which determines the binding affinity of the E2 proteins).
All the genital HPVs studied have four E2 binding sites arranged in a
similar manner within the URR (figure 1.5) Two sites (S3 and S4) are
situated between the CAAT and TATA boxes of the putative E6 promoter
and correspond to the perfect palindromic sequence. A single site
situated another 100 nt upstream (S2) is a perfect palindrome in HPV 6
and 11 but in HPV 18 and HPV 16 this site corresponds to the degenerate
palindromic sequence. Finally, another single site situated a further 400
nt upstream (SI) is a perfect palindrome.
The contribution of each of the E2BS to overall E2 dependent enhancer
activity has been investigated in several studies. Site 1 was originally
thought to play no role in E2 dependent enhancer activity (Phelps and
Howley, 1987; Hirochika et al., 1988; Gius et al., 1988) however
footprinting assays on HPV 18 have found this site to be E2 protected
(Garcia-Carranca et al., 1988) and mutational analyses on HPV 18
(Thierry et al., 1990) and HPV 11 (Broker et al., 1990) have indicated a
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Figure 1.5
Organization of the URR of the common genital HPV types. The 5'
terminus of the URR contains a region rich in AT/GT sequences. A
central enhancer complex is activated by binding of cellular factors.
Shaded circles represent binding sites (S1-S4) for the various E2 proteins.
C and T represent the CAAT and TATA boxes of the E6 promoter
(Hirochika et al., 1988; Chong et al., 1990).
AT/GT Rich S1 Enhancer Complex S2 S3S4
. . . © . /y/////zzzzx _ _ @ . c ©@ t ,
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possible role for this site in the positive regulation of gene expression.
Site 2 is a perfect palindrome in HPV 11 and forms part of an E2
responsive enhancer (Hirochika et al., 1988; Chin et ah, 1989) whereas in
HPV 18 this site is a degenerate palindrome and is not footprinted by E2
(Garcia-Carranca et ah, 1988). Despite this, recent studies suggested that
this site can contribute to E2 dependent negative modulation of gene
expression in HPV 18 (Thierry and Howley, 1990).
When the region containing sites 3 and 4 is cloned with the E6 promoter
in its natural context, transcription is repressed by the full length E2
protein (Thierry and Yaniv, 1987; Bernard et ah, 1989; Chin et ah, 1989).
Since these 2 sites are situated very close to the E6 promoter between
CAAT and TATA boxes, repression may be due to steric interference by
E2 with the binding of transcription factors such as TFIID or RNA
polymerase. In contrast, when cloned in an unnatural context, upstream
of a heterologous promoter, the region containing sites 3 and 4 acts as a
transcriptional enhancer in response to the full length E2 protein. Thus it
would appear that the full length E2 protein can act either as a
transactivator or a repressor depending on the location of the E2 binding
sites in relation to the promoter (Thierry and Yaniv, 1987; Bernard et ah,
1989). Futhermore, recent studies have found that the concentration of E2
protein present is an important factor in determining whether E2 acts as a
transcriptional repressor or a transactivator. It was suggested that E2 may
act as a repressor at high concentration and as a transcriptional
transactivator at low concentration thus regulating its own transcription
and that of E6 and E7 (Broker et ah, 1990).
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1.6.3 Regulation by cellular factors
Cellular hybrids of the aneuploid cervical carcinoma cell line HeLa,
which contains HPV 18, and normal human fibroblasts lose both
tumorigenicity in nude mice (Stanbridge et al., 1982) and expression of
HPV 18 in vivo (zur Hausen, 1986). Hybrids progressively lose
chromosomes and revertants that lose chromosome 11 regain HPV gene
expression and tumorigenicity (zur Hausen, 1986). On the basis of this
evidence it has been suggested that there may be a gene on chromosome
11 coding for a cellular interfering factor (CIF) which suppresses HPV
gene expression (zur Hausen, 1986). In support of this the homologous
enhancer/promoter of HPV 16 functions much more strongly in cells
which lack the short arm of chromosome 11 (Smits et al., 1990).
The HPV URR has been found to contain binding sites for a variety of
cellular factors including nuclear factor 1 (NF1), activator protein 1
(API) and steroid receptors (a glucocorticoid responsive element
(GRE)(figure 1.6). Transcription studies on isolated fragments of the
HPV 16 URR have found that individual sites have little intrinsic
enhancer activity, but may act synergistically when combined (Chong et
al., 1990)(figure 1.6). The precise role of the GRE in HPV transcriptional
control is unknown but it seems likely that it confers some advantage on
the vims since it has been maintained through evolution in many
divergent HPV types. The GRE has been shown to mediate
responsiveness to progesterone. Genital HPV types frequently infect
epithelial cells bearing progesterone receptors. Thus, it is likely that viral
gene expression would be increased in these cells during the female
ovarian cycle and more extensively during pregnancy when warts and
some cervical cancers have been observed to grow rapidly (Chan et al.,
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Figure 1.6
Organization of cellular factor binding sites along the HPV 16 URR. A
fragment reported to contain enhancer activated is underlined with a
shaded bar. Binding sites for nuclear factor I (N), activator protein 1 (A),
glucocorticoid responsive elements (G), novel factors - papillomavirus
associated factor and nuclear factor associated (solid triangles) are
shown. K denotes the core sequence of the keratinocyte dependent
enhancer. The other common genital HPV types have a similar
arrangement. Data redrawn from Chong et al (1990).
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1989).
A keratinocyte dependent enhancer activity has been identified in the
HPV 16 URR (figure 1.6). Essential to this activity is a core sequence
TTNGGTTT (Cripe et al., 1987) found in all the genital HPVs sequenced
so far (Dartmann et al., 1986). The inverted consensus sequence
AANCCAAA is present upstream of several human cytokeratin genes
(Blessing et al., 1987). It has been suggested that the viral element
responds to the same cellular factors as these keratinocyte specific genes.
The effects of specific cellular factors involved in cellular differentiation
on HPV gene expression were studied by Woodworth et al (1990).
Cellular transforming growth factors beta 1 and 2 were found to down
regulate HPV 16 transcription in immortalized non-tumorogenic cervical
cells. Prolonged culture in vitro or malignant transformation of these cells
resulted in partial resistance to this inhibitory effect on HPV
transcription which varied according to the degree of cellular
differentiation. Epidermal growth factor (EGF) down regulated HPV 16
E6/E7 expression in an immortalized human keratinocyte cell line. An
EGF responsive element has been identified and found to overlap the
region previously mapped to the keratinocyte dependent enhancer
(Yasumoto et al., 1991).
1.7 Alterations in the Viral Upstream Regulatory Region (URR)
Viral variants with sequence alterations within the URR have been found
in genital carcinomas and unusual lesions and it has been suggested that
as these variants are likely to have an altered pattern of gene expression,
they may contribute to the neoplastic process.
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There are several reports of sequence alterations in the URR of the low
risk HPVs. Sub types HPV 6vc and HPV 6T-70 both isolated from
invasive vulvar carcinomas had deletions and/or insertions in the 5'
AT/GT rich region of the URR (Rando et al., 1986; Kasher and Roman,
1988). It was proposed that the duplication of these sequences in the
URR might be sufficient for conversion to a malignant phenotype on the
basis that similar sequences found in the human genome are capable of
enhancing gene expression. However, a subsequent study showed that
HPV 6T-70 and an HPV 6 isolate from a benign lesion had similar
relative enhancer activities and transforming potentials (Farr et al., 1991).
While recent reports describe DNA-protein binding interactions and
enhancer activity in the 5' end of the HPV 11 URR it is still difficult to
ascertain the significance of sequence alterations within this region
(Auborn and Steinberg, 1991).
HPV 6ma was cloned from a condyloma of the nipple. This isolate
contained a 236bp duplication of sequences in the 3' region of the URR
incorporating an NF1 site, the cytokeratin octamer and an E2 binding
site. Interestingly a fragment containing the entire duplication was found
to have increased enhancer activity. It was suggested that this duplication
may influence early gene expression and possibly tissue tropism (Kulke
et al., 1989).
Boshart and zur Hausen (1987) described another subtype of HPV 6 -
HPV 6d - which they isolated from a Buschke-Lowenstein tumour. This
subtype differs from HPV 6b by a 459bp duplication of the 3' end of the
URR. This duplication contained many of the putative control elements
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for early gene transcription which the authors suggest may influence the
biological potential of that virus. The first report of a tandem duplication
of the entire URR was of an HPV 11 isolate found in a lung metastasis
from a patient with chronic laryngotracheobronchial papillomatosis
(Byrne et ah, 1987).
Until recently there have been relatively few reports of sequence
alterations in the URR of the high risk HPV types. The first indication
that viral variants may be transmissible came from Tidy et al (1989) who
found two independently derived cervical carcinomas infected with an
episomal variant of HPV 16. This variant had a deletion of a large portion
of the 3' end of the URR which included the GRE, the keratinocyte
dependent enhancer, E2 binding sites, a CAAT and a TATA box.
Preliminary reports describe four further variants of HPV 16, with
sequence alterations in the 5' AT/GT rich region of the URR, found in
cases of vulvar bowenoid papulosis, vulvar condyloma and early vulvar
carcinoma (Fang et al., 1990; Donghi et al., 1990).
1.8 Physical state of HPV DNA in Cervical Tumours
Another mechanism which could alter the normal pattern of viral gene
expression and thus contribute to the neoplastic process is the integration
of HPV DNA into the host genome. Papillomavirus DNA is well known
to exist as an extrachromosomal episome in benign cervical lesions
whereas, in most human cervical carcinomas and carcinoma-derived cell
lines HPV 16 and 18 have been found integrated into the human
chromosome (Boshart, 1984; Durst et al., 1985; Pater and Pater, 1985;
Shirasawa et al., 1987; Tidy et al., 1989). In one study of 100 HPV
positive CIN lesions, only 3 showed integrated HPV DNA and these
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were higher grade dysplasias. In contrast, the same study detected
integrated HPV DNA in 81% of 69 cervical carcinomas (Cullen et al.,
1991). Integration of high risk HPV types has also been shown to occur
in experimental models. Human genital keratinocytes immortalized by
HPV types 16, 18, 31 or 33 contain integrated and transcriptionally active
viral genomes whereas HPV 6 or 11 transfected cells are not
immortalized and contain only extrachromosomal viral DNA
(Woodworth et al., 1989).
1.8.1 Effects of integration on the viral genome
In the viral genome, the integration event most often dismpts the El or
E2 ORFs leading to the functional inactivation of the E2 gene which
encodes positive and negative regulatory functions for the viral promoter
element in the URR (Choo et al., 1987; Lambert et al., 1987b; Cripe et
al., 1987). While other viral genes and functions may be lost through
focal deletion or decoupling from the URR, the E6 and E7 transforming
genes and the URR are invariably retained (Pater and Pater, 1985;
Schwarz et al., 1985; Baker et al., 1987). These observations have led to
speculation that dismption of the E2 repressors may allow over-
expression of the E6 and E7 oncoproteins, promoting the development of
neoplasia (Choo et al, 1987). Viral integration within E1/E2 region could
also mean the loss or uncoupling of the usual viral signals which
terminate transcription. Thus transcription of E6 and E7 genes would run
on into adjacent host DNA until terminated by host signals. In theory,
this could give rise to an E6/E7 coding mRNA with increased stability or
translatability possibly leading to increased levels of E6/E7 proteins
(Arends et al., 1990).
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1.8.2 Effects of integration on the cell genome
The cause of viral integration is unknown but it has been suggested that it
may be induced by carcinogens or due to intrinsic properties of the virus.
The monoclonal pattern of viral integration indicates that this occurs prior
to expansion of the malignant clone of cells.
While there is no unique site within the host genome at which viral
integration occurs, evidence that it is not an entirely random process has
come from a study by Choo et al (1990) who showed that HPV 16
integration in a cervical carcinoma had been guided or influenced by
short regions of sequence homology within the viral genome and cellular
DNA. Furthermore, fragile sites and proto-oncogene locations appear to
be preferential targets for viral integration (Popescu and DiPaolo, 1989).
The significance of this event is discussed below.
1.9 HPV and Cellular Oncogenes
In HPV-associated cervical cancers the results of several studies indicate
the probable involvement of cellular oncogenes. In a series of HPV 16 or
18 positive cervical carcinomas amplification of oncogenes c-myc and c-
Ha-ras was correlated with advanced tumour stage (Riou et al., 1984).
Overexpression of c-myc was also correlated with poor prognosis for
early stage invasive carcinomas with an eight fold greater incidence of
early relapse compared to those with normal c-myc expression (Riou et
al., 1987). A further study found that a high proportion of HPV 16 or 18
positive cervical carcinomas with mutated or deleted c-Ha-ras genes also
exhibited overexpressed or amplified levels of c-myc suggesting possible
complementation between these two oncogenes in tumour progression
(Riou et al., 1988).
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Interestingly, studies on the integration sites of HPV 18 in HeLa and C4-
1 cervical carcinoma cell lines found that the vims had inserted within 40
kb upstream of the c-myc gene and that the level of c-myc mRNA was
increased in both cell lines raising the possibility that HPV integration
caused cw-activation of c-myc (Durst et al., 1987b). The influence of
HPV integration on nearby proto-oncogenes or other genes involved in
cellular differentiation remains to be examined.
1.10 Additional Risk Factors for Cervical Neoplasia
Cigarette smoking, oral contraceptives, Herpes Simplex Vims (HSV)
infection and immune status have all been suggested as possible risk
factors for the development of cervical cancer. Epidemiological studies
have found a low but consistent increase in relative risk due to heavy or
prolonged smoking and a probable increase from prolonged use of oral
contraceptives. Tobacco metabolites and mutagenic activity have been
detected in the cervical mucus of smokers indicating the opportunity for a
direct carcinogenic effect (Brinton and Fraumeni, 1986).
Herpes simplex vims has the potential to act as a hit and mn initiator and
recent studies have found that HSV-2 is capable of converting HPV-16
immortalized human genital keratinocytes to tumorigenicity (DiPaolo et
al, 1990), However, a prospective investigation by Vonka et al (1984)
revealed no relationship between HSV-2 infection and subsequent
neoplasia among a cohort of women.
An increased risk of HPV infection and CIN has been observed in renal
allograft patients (Alloub et al., 1989) who are immunosuppressed.
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Recurrence of condylomata and CIN appears to be influenced by immune
suppression resulting from various causes (Porecco et al., 1975; Sillman
et al., 1984; Halpert et al., 1986). A recent study found a high risk of
cervical carcinoma for women with HLA-DQw3, a histocompatability
antigen (Wank and Thomssen, 1991), suggesting a role for the immune
response genes.
1.11 A Multistage Model Cervical Carcinogenesis
The current view of cervical neoplasia is that of a multistage disease
which develops sequentially from CIN 1 through CIN 3. All CIN lesions
are potentially reversible. Further progression to invasive carcinoma
represents a qualitatively different and irreversible change.
Epidemiological studies show a clear correlation between HPV infection
and cervical neoplasia and the oncogenic potential of the vims has been
demonstrated in many transformation studies. However, HPY infection
does not appear to be the only factor involved in the development of
cervical cancer, as many cases of HPV infection do not develop into
cervical cancer. In keeping with the multistage model for cervical
carcinogenesis additional events or factors are thought to be required for
neoplastic progression.
A model of events which may occur in development of cervical cancer is
shown in figure 1.7. In this model infection of epithelial stem cells with
HPV provokes intraepithelial neoplasia presumably due to the interaction




A model of possible events contributing to the development of cervical
cancer. HPV infection of basal stem cells in the cervical epithelium,
perhaps aided by co-factors provokes CIN. HPV variants with URR
alterations or the integration of HPV DNA may contribute to neoplastic
progression through an altered pattern of viral gene expression.
Inactivation of oncosuppressors p53 and Rb and oncogene activation may
also play a role in conversion to invasive carcinoma.






Subsequent progression may involve an altered pattern of gene
expression such that the viral E6 and E7 transforming genes are
expressed to a high level. Integration of HPV DNA of the high risk types
into the host genome has the potential to alter viral gene expression in
this way. The integration event results in conservation of intact
URR/E6/E7 DNA sequences and inactivation or loss of expression of E2
which encodes regulatory proteins for viral transcription and LI and L2
which may provide targets for an immune response. Alternatively, HPV
variants of high or low risk type with alterations to the URR may have an
altered pattern of gene expression such that E6 and E7 are overexpressed.
Evidence exists to support degradation and functional inactivation of
oncosuppressor proteins p53 and Rb by the E6 and E7 proteins of the
high risk HPV types. Loss of control of viral gene expression by the
putative CIF genes on chromosome 11 may also contribute to the
neoplastic process by allowing continuous expression of viral genes.
Activation of the c-myc and c-Ha-ras-1 oncogenes may play a role: myc
activation appears to correlate with early stage tumours and ras activation
with late stage tumours.
While this model for cervical carcinogenesis explains some of the events
likely to be involved in the development of invasive carcinoma there are
many aspects which require further investigation and clarification. In
order to establish a role for HPV in cervical cancer it is important to have
some indication as to the prevalence of the vims in the normal
population. Reports on the prevalence of HPV DNA in the normal
population vary widely and some investigators have found a high
prevalence of HPV 16 in their control cases casting doubt on the role of
HPV in cervical cancer (Schneider et al., 1987; Young et al., 1989).
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These widely varying rates are most likely to be a consequence of the
different detection or cervical sampling methods used or the source of the
control subjects (Munoz et al., 1988). Application of sensitive detection
assays to focussed cervical samples from control groups representative of
the normal population should help to clarify this matter.
Whether the usual pathway of progression from HPV infection to
invasive cancer is sequential from CIN 1 via CIN 2 and CIN 3 or direct
from any of these to cancer is not known. Few investigators appear to
have addressed this question and consequently there is little accurate data
on HPV prevalence at each stage of the disease.
The common HPV types are believed to differ in oncogenic potential and
thus have been assigned differing levels of risk. HPV 6 and 11 appear to
confer a low risk and HPV 16 and 18 a high risk of malignant
transformation. Possible differences in behaviour of associated tumours
may exist amongst the high risk HPV types with HPV 18 more prevalent
in glandular than squamous cervical carcinomas and having a greater
tendency toward rapid progression. Further studies aimed at generating
accurate data on the prevalence of individual HPV types in CIN,
squamous and glandular carcinomas may prove useful in substantiating
these findings.
In recent years HPV variants of both high and low risk types with large
scale alterations to the URR have been discovered. While it has been
suggested that lesions containing these variants may have a greater
tendency toward neoplastic progression little is known of their overall
prevalence in CIN or cervical carcinomas. Integration of high risk type
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HPV DNA into the host genome is thought to play an important role in
neoplastic progression. However the precise stage in cervical
carcinogenesis at which this event occurs is unclear. Investigation of both
the prevalence of HPV variants in CIN and carcinoma and the stage in
the CIN-cancer sequence at which integration usually occurs will require
the design of new sensitive assays which are applicable to small CIN
biopsies.
1.12 Aims
This study aimed to establish a more precise role for HPV in the
development of cervical cancer and also to determine the key stages in
the neoplastic process at which HPV contributes. The approach was to
correlate the presence of specific high and low risk HPV types, sequence
alterations within the HPV URR, and the physical state of HPV DNA,






Sixty cervical biopsy specimens were obtained from women referred for
diagnosis or treatment because of abnormal smears to Elsie Inglis
Colposcopy Clinic, Edinburgh. Abnormal aceto-white cervical lesions
detected colposcopically were sampled by punch biopsy and immediately
snap frozen in liquid nitrogen. Adjacent sections were taken for HPV
detection and histological assessment. Control cervical blocks were taken
at forensic autopsy from young women (within 24 hours of accidental
death) courtesy of Professor Busuttil, Forensic Medicine Unit,
Department of Pathology, Edinburgh. Two transverse sections were taken
from the transformation zone of the control cervices, one was
immediately snap frozen in liquid nitrogen, the other was fixed in neutral
buffered formalin and processed as a paraffin block for histological
assessment. Adjacent sections of the frozen tissue were taken for HPV
detection and additional histological assessment.
Formalin-fixed paraffin-embedded tissues of 26 cases of squamous
carcinoma, 16 cases of adenocarcinoma and 4 cases of adenosquamous
carcinoma diagnosed as part of the routine diagnostic service were
chosen from the file of routine surgical specimens of the University of
Edinburgh. The specimens were cone biopsies or hysterectomies
performed between 1982 and 1990.
2.2 Histopathological Examination
Tissue sections from all specimens were stained with haemotoxylin-
eosin. Every case of carcinoma was also stained with Alcian blue/
periodic acid Schiff. Histology of all specimens was assessed
independently by two experienced pathologists - Dr M Arends and Dr E
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Duvall - according to standard criteria (Ferenczy and Winkler, 1987).
Grade of CIN was diagnosed on the basis of whether abnormal cells
filled one third, two thirds or the entire thickness of the epithelium,
independent of koilocytic change. In a small number of the CIN cases
(equally distributed amongst CIN 1, CIN 2 and CIN 3) final histological
assessment was resolved by consensus. The diagnosis of squamous
carcinoma was on the basis of evidence of squamous differentiation,
either keratinization or prickle formation. Glandular carcinoma was
diagnosed on the basis of mucin secretion and formation of glandular
structures. Adenosquamous carcinoma was diagnosed in cases which
showed a mixed pattern: at least 10% squamous and 10% glandular
differentiation. Normal exocervical and endocervical epithlelium and
glands were identified in all the tissue sampled at autopsy.
2.3 Oligonucleotide Selection and Synthesis
HPV DNA sequences, derived from the EMBL genetic sequence
database, were analysed for the selection of PCR primers and oligoprobes
using the University of Wisconsin (UW) Genetics Computer Group
Software (Cameron, 1988; Devereux et al., 1984). Criteria on which
selection was made are explained in the relevant chapters.
Oligonucleotides suitable as primers and probes were synthesized on an
Oswel Gene Synthesiser (Dept. of Chemistry, University of Edinburgh,
UK) and were HPLC purified. During synthesis a biotin moiety, on a 15
carbon atom linker arm, was added to the 5' end of the oligonucleotide
probes.
2.4 Preparation of Materials for PCR
Two 20um frozen sections were cut from punch biopsies of cervical
40
intraepithelial neoplasia or normal cervix. The sections were briefly
thawed on the surface of ice-chilled distilled water in a 1.5ml Eppendorf
tube. Concentrated PCR solution (detailed below) was added to give a
final volume of lOOul and this was heated to 98°C for 10 min prior to
amplification. Heat denaturation for longer periods was tested but no
difference in efficiency of PCR was observed.
Two 20um sections cut from paraffin blocks of cervical carcinoma were
placed in a 1.5ml Eppendorf tube, suspended in 200ul digestion buffer
(lOOmM NaCl, lOmM Tris-Cl, 25mM EDTA, 0.5% SDS, pH 8.4)
containing O.lmg/ml proteinase K and incubated at 37°C for five days.
Nucleic acid was purified by an organic extraction step. An equal volume
(200ul) of phenol:chloroform:iso-amyl alcohol (25:24:1) was added to the
proteinase K digests, mixed and centrifuged to separate the aqueous and
organic layers. The upper aqueous layer was collected and the extraction
repeated. A final extraction was carried out using an equal volume of
chloroform: iso-amyl alcohol (24:1). The nucleic acid was then
precipitated with one half volume (lOOul) 7.5M ammonium acetate and
two volumes (600ul) of cold ethanol at -20°C for 16-20 hours, spun down
(1300 rpm, for 15 minutes), vacuum dried and dissolved in 20ul TRIS-
EDTA buffer for three days. 98ul of PCR solution was added to 2ul of
extracted nucleic acid prior to amplification.
The cultured cells, HeLa, SiHa and Raji, were obtained from the
American Type Culture Collection and grown in vitro in Dulbecco's
MEM medium with 10% heat inactivated foetal calf serum by standard
methods. Up to 104 cells were suspended in 20ul phosphate buffered
saline (PBS) and prepared for PCR by boiling for 15 min. 80ul
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concentrated PCR solution was added just prior to amplification.
2.5 Polymerase Chain Reaction
The PCR solution consisted of reaction buffer (50mM KC1, lOmM Tris-
HC1 (pH8.3 at room temperature), 1.5mM MgCl2, 0.01% gelatin),
200uM of each dNTP, l.OuM of each primer, 2-2.5 units Taq
Polymerase. PCR solution was added to template to give a final volume
of lOOul and overlaid with lOOul mineral oil. Samples were subjected to
30-35 cycles of PCR on an automated heating block (Hybaid), each cycle
consisting of DNA duplex denaturation at 94°C for 1 min, primer
annealing at 45-55°C for 2 min and DNA synthesis by primer extension
at 72°C for 3 min. During the final cycle, the extension step lasted 10
min. The reaction product was electrophoresed on a l%-4% agarose
(Nusieve GTG, Seakem GTG) gel containing 2ug/ml ethidium bromide in
Tris-Borate buffer (Kodak) along with a DNA size marker, and visualised
under UV light.
2.6 Procedures to Minimise the Risk of Contamination
Stringent precautions were taken to minimise the risk of contamination of
the PCR solution with HPV DNA from unwanted sources. Tissue
sections from different cases were cut using either separate microtome
blades or previously unused regions of the same blade (when taking
sections from small punch biopsies). Sections cut from a block of tissue
not containing HPV (eg myocardium) were included where appropriate,
to investigate the possibility of transfer of HPV DNA from case to case,
during section cutting or proteinase K digestion. Separate laboratories
were used for preparation of the PCR solution, amplification in the
automated heating block, and analysis of the amplified DNA by gel
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electrophoresis or dot blot hybridisation. The components of the PCR
solution were prepared in small aliquots prior to use, and added to the
reaction in a class II biological safety cabinet, using positive displacement
pipettes exclusively dedicated to this purpose. Whilst setting up the
reactions the operator adopted a microbiological standard sterile
technique and wore disposable gloves.
2.7 Amplfication of Reference Gene
All cases found to be PCR negative for the 5 HPV types were checked for
amplifiable DNA and absence of Taq polymerase inhibition using a
separate set of specific primers for a reference gene c-Ha-ras (primer 1,
5'GACGGAATATAAGCTGGTGG3'; primer 2, 5'TGGATGGTCAGCGCACTCTT3')
(Verlaan de-Vries et ah, 1986). The amplified products of all cases found
to be HPV positive in the PCR assay were subjected to confirmation by
dot blot hybridisation as described below.
2.8 Dot Blot Hybridisation
Nitrocellulose filters were pretreated with distilled water followed by 15
X SSC (standard sodium citrate). The amplified DNA was resuspended in
20ul TE buffer and serially diluted ten- and one hundred-fold in 15 X
SSC. lOul samples, made up to a final volume of lOOul in 15 X SSC,
were subjected to heat denaturation at 98°C for 5 min, and vacuum
blotted onto nitrocellulose filters using "Hybridot" manifold (Gibco-
BRL). The sample wells were washed through with a further lOOul 15 X
SSC.
The filters were baked at 80°C for 2h and prehybridised for lh at 42°C
in 5 X SSC, 25mM NaH2PC>4 (pH6.5), 5 X Denhardts solution, 0.1%
sodium dodecyl sulphate (SDS) and 200ug/ml denatured salmon sperm
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DNA. The prehybridisation solution was replaced with the hybridisation
solution which contained the same components with the addition of
0.8uM biotinylated oligonucleotide probe (heated to 98°C for 10 min
before use to denature any secondary structure), and differing
concentrations of deionised formamide optimized for the different probes
(0%, 10%, 15%, 20% and 0% for HPV types 6, 11, 16, 18 and 33
respectively)(Albretsen et al., 1988). Filters were hybridised at 42°C for
16-20h, washed twice at 20°C in 2 X SSC with 0.1% SDS, twice at 42°C
in 0.5 X SSC with 0.1% SDS and baked at 80°C for lh.
Bound, biotinylated probe was detected using a modification of the
"Blugene" protocol (Gibco-BRL). Non-specific streptavidin binding sites
were blocked by incubating the filters for 20 min at 42°C in a solution of
0.1M Tris-HCl (pH7.5), 0.1M NaCl, 2mM MgCl2, 0.05% Triton X-100
(buffer 1) with bovine serum albumin (Sigma) added to a final
concentration of 3% (buffer 2). The filters were baked at 80°C for lh,
rehydrated in buffer 2 for 10 min, incubated at 20°C for 10 min in 2ug/ml
streptavidin solution (Gibco-BRL), washed twice in buffer 1, and
incubated at 20°C in lug/ml biotinylated alkaline phosphatase solution
(Gibco-BRL) for 10 min. The filters were then washed twice in buffer 1
at 20°C for 10 min and twice in 0.1M Tris-HCl (pH9.5), 0.1M NaCl,
50mM MgCl2 (buffer 3) at 20°C for 10 min. Bound alkaline phosphatase
was visualised by incubation in the dark, at 20°C in a solution of
0.33mg/ml nitro-blue tetrazolium (NBT) and 0.166mg/ml 5-bromo, 4-
chloro, 3-indolyl phosphate (BCIP) in buffer 3. After l-2h, deposition of
the blue-purple coloured reaction product was terminated by immersing
the filters in 20uM Tris (pH7.5), 5mM EDTA and the filters were baked
at 80°C for 1-2 min.
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2.9 Restriction Enzyme Mapping
Amplified DNA products were concentrated by ethanol precipitation and
resuspended in 20ul restriction enzyme buffer. These were digested with
appropriate enzymes at 37°C for 16-20h. lOul DNA solutions of both
HPV 6b and 11 were restricted with Ddel (22 units)(Sigma), HPV 16 and
18 with Hinfl (20 units)(Sigma) and HPV 33 with Dral (24
units)(Amersham). The digested DNA was subjected to electrophoresis at
50v for 4h on a 2.5% agarose gel in Tris-Borate buffer (Kodak)
2.10 Anchor PCR
lOug cloned HPV 16 plasmid DNA was digested with Aatll (16 units)
(BCL) in a total volume of 20ul at 37°C for 16-20h in triplicate reactions.
The DNA from one reaction was electrophoresed at 50v on a 1% agarose
gel to ensure digestion had been complete.
DNA from the second reaction was used to check the efficiency of the 3'
tailing reaction: digested DNA was tailed with terminal deoxynucleotidyl
transferase (TdT)(15 units)(Gibco-BRL) in 40ul reaction mixture
containing tailing buffer (2mM C0CI2, 0.1M potassium cacodylate (pH
7.2), 200uM DTT )(Gibco-BRL), 2.5uM dATP and 4ul [P32] dATP (10
mCi/ml, >400 Ci/mmol) for lh at 37°C. Reaction products were
electrophoresed on a 1% agarose gel which was then exposed to X-ray
film for 16-20h at 20°C sealed in a light tight cassette.
Digested DNA from the remaining reaction was tailed with TdT (15
units) in a 40ul reaction mixture containing tailing buffer (as above) and
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2.5uM dATP for lh at 37°C. For anchor-PCR, lOul of tailed DNA was
added to a reaction mixture containing 50mM KC1, lOmM Tris-HCl
(pH8.3 at room temperature), 1.5mM MgCl2, 0.01% gelatin (PCR
buffer), 200uM of each dNTP, l.OuM adapter primer, l.OuM HPV
specific primer, 0.2uM hybrid primer to give a final volume of lOOul. The
mixture was then overlaid with paraffin oil to prevent evaporation and
incubated at 94°C for 5 min for DNA denaturation. After cooling to
72°C, 2.5 units of Taq Polymerase (NBL) was added. To allow for the
annealing of the hybrid primer to poly A tails and subsequent extension,
the first cycle of amplification was annealed at 55°C for 5 min and
extended at 72°C for 40 minutes. The following 40 cycles of
amplification were denatured at 94°C for 1 min, annealed at 55°C for 2
min and extended at 72°C for 4 min (with the exception of the final cycle
which was extended for 15 min). 20ul of the final reaction products was
electrophoresed on a 1% agarose gel (Seakem GTG) containing 2ug/ml
ethidium bromide in Tris-Borate buffer (Kodak) at 75v for 2h with a
DNA size marker - the lkb ladder (fragment sizes: 12,216; 11,198;
10,180; 9,162; 8,144; 7,126; 6,108; 5,090; 4,072; 3, 084; 2,036; 1,635;
1,018; 516/506; 394; 344; 298; 220; 200; 154; 142; 75)(Gibco- BRL).
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CHAPTER 3




A variety of techniques have been used to detect HPV in clinical
samples. Until recently most studies used hybridisation techniques such
as Southern blot, tissue in situ, dot blot and filter in situ (FISH)
hybridisation (Lorincz et al., 1987; Tase et al., 1988; Pater et al.,1986; de
Villiers et al., 1987). Southern hybridisation is a sensitive method of
detecting gene sequences but it is expensive, time consuming, labour
intensive and requires relatively large quantities of fresh tissue. Tissue in
situ hybridisation allows visualisation of target DNA sequences in
specific cells but can lack sensitivity and prolonged incubation times
mean that the technique usually takes days to perform. The FISH and dot
blot techniques are less laborious but are of low specificity and
sensitivity.
A recently developed technique, polymerase chain reaction (PCR), is
capable of amplifying very small amounts of specific DNA sequences
within hours to a level detectable by gel analysis. The PCR is an in vitro
method for the enzymatic synthesis of specific DNA sequences, using
two oligonucleotide primers that hybridise to opposite strands and flank
the region of interest in the target DNA. Repetitive cycles of template
denaturation, primer annealing, and the extension of the annealed primers
by DNA polymerase results in the near exponential accumulation of a
specific DNA fragment whose termini are defined by the 5' ends of the
primers (figure 3.1). Because the products of one cycle can serve as a
template in the next, the number of target DNA copies approximately
doubles at every cycle. This highly sensitive technique has been used to
identify one copy of HPV DNA in 10^ cells (Young et al., 1989) and has
been successfully applied to tissue which has been formalin fixed and
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Figure 3.1
The standard PCR reaction involves repeated cycling of three steps: (1)
denaturation at 94°C, (2) primer annealing at between 42°C and 60°C
dependent upon primer constraints, (3) extension of annealed primers by
Taq polymerase at 72°C. The time for each step is specific to the system
used. Repeated cycling of these three steps results in near logarithmic














paraffin wax embedded for histological examination (Shibata at al., 1988)
In this study, a detection assay was designed which involved PCR
amplification of HPV DNA using primers specific for each HPV type.
Amplified products were identified by gel electrophoresis and separately
by hybridisation with oligoprobes specific for each HPV type. The assay
was optimized for absolute HPV type specificity, sensitivity and
applicability to tissue from different sources.
3.2 Results
3.2.1 Design of oligonucleotides for the HPV detection assay
Several factors were taken into account when designing primers and
probes for the HPV detection assay. Target sequences for oligonucleotide
binding had to be conserved following integration and could therefore
only be chosen from the URR, E6 or E7 ORFs (figure 3.2). As
oligonucleotide sequences had also to be unique to each HPV type for the
assay to be HPV type specific, the E6 and E7 genes were searched for
regions of HPV type specific sequence divergence.
To distinguish between the most similar HPV types, the University of
Wisconsin (UW) computer program COMPARE was used. The E6 genes
of HPV 6b and 11, HPV 16 and 18, HPV 16 and 33 and HPV 18 and 33
were compared . Using the the UW program DOTPLOT, regions with
dissimilar sequences appear as gaps in the diagonal line of colinear
homology in the dot plots (figure 3.3). To examine these dissimilar
sequences at nucleotide level, the UW GAP program was used. This
program allows the determination of the exact extent of base
mismatching of the most similar HPV types. For each HPV type, three
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Figure 3.2
Pattern of integration of HPV DNA by disruption of the circular viral
genome at the E1-E2 region in three cervical carcinoma cell lines
(SW756, HeLa, C4-1). The transforming genes E6 and E7, adjacent to
the viral promoters and enhancers in the upstream regulatory region
remain intact, whilst other viral coding sequences are not always
retained. Solid lines represent host cell DNA. The target sequence
(hatched box) for amplification by PCR, directed by HPV type-specific
primers (arrows), lies within the E6 gene. Data redrawn from Schwarz et
al (1985).
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Computer generated dotplots of the comparison of homologies of the first
1000 nucleotides (which contain the E6 and E7 sequences) of (1) HPV 6b
with HPV 11, using a window of 20 bases in length and a stringency of
15, with each dot plotted representing the occurrence of 15 or more
identical bases out of 20 being compared at that position, and of (2) HPV
16 with HPV 18, using a stringency of 13 with a window of 20 bases, (3)
HPV 16 with HPV 33, using a stringency of 13 and a window of 20 bases
and (4) HPV 18 with HPV 33, using a stringency of 13 and a window of
20 bases. The high density of dots along the diagonals illustrates the
strong colinear homologies, and the gaps indicate the local regions of
relative nucleotide mismatc ling which are appropriate for use as type-
specific PCR primers or probe sequences.
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regions with a high degree of mismatching were selected - one at either
end for primers 1 and 2 and a central sequence for an oligoprobe.
Having found regions of dissimilarity between HPV types, sequences
suitable for efficient primers and probes were chosen on the basis of
several other criteria, including GC content, predicted secondary stmcture
and 3' complementarity as suggested in guidelines by Saiki et al (1989).
An even distribution of GC to AT bases is desirable to allow use of
stringent annealing temperatures. Sequences with significant secondary
structure are best avoided as this is thought to interfere with primer
annealing during PCR. As there are no guidelines to indicate what
constitutes "significant" secondary stmcture, an arbitrary decision was
made to consider only sequences where predicted secondary stmctures
known as stem loops had a maximum of 5 base pairings as predicted
using UW programs FOLD and SQUIGGLES (figure 3.4).
Complementarity between the 3' ends of primer pairs can lead to the
formation of PCR artefacts known as "primer dimers" which can reduce
the yield of specific amplified product. Previous data have suggested that
two terminal complementary bases does not significantly favour primer
dimer formation and therefore, primer sequences with a maximum of 2
complementary bases at the 3' end were considered.
The sequences chosen for use as oligonucleotide primer and probes in the
detection assay are shown in table 3.5. These sequences had a low
enough level of homology with the other HPV types that they would not
be expected to bind at temperatures of between 40°C-60°C. To maximise
sequence specificity, oligonucleotides had a minimum length of 20 bases
which permitted use of high stringency washing conditions for probes
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Figure 3.4
Computer generated prediction of the secondary structure of HPV 16
primer 2. This primer is predicted to have 4 base pairs in the stem loop.
The 3' end of the primer - which is important for precise initiation of




Nucleotide sequence (5' to 3') of the pairs of PCR primers for each HPV,
their positions within the viral genome according to the EMBL database
nomenclature and the percentage homology (H) with the equivalent DNA
sequence of the most closely matching alternative HPV genome (C).
HPV
PRIMER/
PROBE SEQUENCE (5' to 3') POSITION H C
6b Primer 1 OCT GTT TCG AGG CGG CTA TCC ATA 260-283 58 1 1
6b Primer 2 GTA CAA TTT AGO TTT ATG AAC CGC GCC TTG GTT 464-496 64 1 1
6b Probe TAA ACA AGA CAT CTT AGA CGT GCT A AT TCG GTG C 380-413 71 1 1
11 Primer 1 TGT GTG GCG AGA CAA CTT TCC CTT 260-283 58 6b
11 Primer 2 TGG TTA TTT AGT TTT ATG AAG CGT GCC TTT CCC 464-496 64 6b
11 Probe CAA TG A AGA TAT TTT AAA AGT GTT A A AT TCG TTG T 380-4 13 71 6b
16 Primer 1 CTG CAA GCA ACA GTT ACT GCG ACG 199-222 42 18
16 Primer 2 CAT ACA TCG ACC GGT CCA CC 495-514 35 18
16 Probe TAT TAA CTG TCA AAA GCC ACT GTG TCC TG A 412-441 65 18
18 Primer 1 AAA CTA ACT AAC ACT GGG TTA TAC A 378-402 44 16
18 Primer 2 ATG GCA CTG GCC TCT ATA GT 502-521 35 16
18 Probe CCT GCG GTG CCA GAA ACC GTT GAA TCC AGC 419-448 65 16
33 Primer 1 AAC AGT TAA AAA ACC TTT AAA 378-398 48 16
33 Primer 2 AGT TTC TCT ACG TCG GGA CCT C 528-549 41 16
33 Probe AAA ACG ACA TGT GG A TTT AAA CAA ACG ATT T 453-483 50 16
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and higher primer annealing temperatures. The sequences of the other
HPV types were searched using the UW program FIND to ensure that the
selected primers and probes would not cross hybridise. The GC content
of the primers chosen varied from 39% to 60% with the exceptions of
HPV 18 primer 1 (32%) and HPV 33 primer 1 (19%). Stem loops with
equivalent or less than 5 base pairings were predicted for all the primers.
No significant complementarity between the 3' ends of paired primers
(for each HPV type) was identified, thus limiting the risk of primer dimer
formation.
3.2.2 Optimization of conditions for the detection assay
The PCR protocol for amplification of target HPV DNA was varied to
find optimum reaction conditions using cloned HPV DNA as template
and an initial primer annealing temperature of 42°C. The optimum
conditions were considered to be those which gave the highest yield of
specific product with the lowest incidence of background judged by
subjective examination of agarose gels. For each new batch of enzyme,
reactions were set up which had final MgCl2 concentrations of 1.5mM,
2.5mM and 3.5mM. In every case 1.5mM was found to be optimal. Step
times for denaturation, primer annealing and extension of lmin, 2min and
3 min respectively were found to be more efficient than 30 sec, 1 min and
1 min or 1 min, 1 min and 2 min. The primer annealing temperature (Ta)
was raised in a series of reactions by 2°C to 60°C. A final Ta of 50°C
produced successful amplification using all primer pairs (figure 3.6). This
optimization of Ta increases specific binding of primers to target HPV
DNA enhancing discrimination against incorrectly annealed primers and
reducing misextension of incorrect nucleotides at the 3' end of primers.
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Figure 3.6
Agarose gel electrophoresis of amplified DNA using type-specific pairs
of primers with cloned DNA for types (a) HPV 6b (fragment length
237bp), (b) HPV 11 (237bp), (c) HPV 16 (316bp), (d) HPV 18 (144bp)
and (e) HPV 33 (172bp). A lkb ladder marker track (M) is included in
this and many subsequent gel photographs.
M a b c d e
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The PCR "plateau" effect was taken into account when deciding upon the
number of cycles of PCR to be used in the detection assay. The plateau
effect is a term used to describe the attenuation in the exponential rate of
product accumulation that occurs during late PCR cycles (Saiki, 1989;
Innis and Gelfand, 1990). The point at which any PCR reaction reaches
its plateau depends primarily on the number of copies of target DNA
originally present in the sample. An important consequence of reaching
plateau is that an initially low concentration of non-specific products
resulting from mispriming events may continue to amplify preferentially.
It is known that HPV copy number can vary considerably in different
clinical samples eg. carcinoma derived cell lines SiHa and CaSki contain
1-2 and 400 - 500 copies of HPV 16 respectively (Pater and Pater, 1985).
To achieve maximum amplification yet avoid amplifying background
products associated with the plateau, the standard 30 cycles as suggested
by Saiki (1989) was used. To determine the threshold sensitivity of the
assay 35 cycles of PCR were used in order to increase the probability that
the plateau was reached for this small number of HPV copies.
Successful amplification of HPV DNA was achieved using a variety of
templates including frozen sections, paraffin wax sections and DNA
extracted and purified from both fresh tissue and paraffin wax sections
(figure 3.7).
3.2.3 Validation of the detection assay for HPV type specificity
The HPV type specificity of the assay lies in both the primers and the
oligoprobes. Specificity of primer directed amplification was assessed for
each set of primers with template DNA of the 5 HPV types, 6b, 11, 16,
18 and 33. Amplified DNA fragments were only generated when primer
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Figure 3.7
Agarose gel electrophoresis of amplified DNA using HPV 11 primers
with samples of a vulvar wart harbouring HPV 11, in the form of
extracted DNA (a), frozen sections (b) and paraffin wax embedded
sections (c); a lkb ladder marker track (M) and a negative control track
(N) are included.




pairs were used with template DNA of the appropriate type. No
amplification occurred when primers of one type were applied to
template DNA of another (figure 3.8).
Confirmation that amplified DNA contained the appropriate HPV DNA
target sequence was obtained from dot blots hybridised with type specific
oligoprobes and from restriction endonuclease mapping using enzymes
which generate diagnostic fragments from each of the 5 HPV types
(figure 3.9).
To establish type specificity of oligoprobe hybridisation, the amplified
target DNA from all 5 HPV types were dot blotted onto nitrocellulose
filters and tested for cross-hybridisation using the 5 HPV type-specific
oligoprobes. Each oligoprobe generated a positive hybridisation signal
only with amplified target DNA of the same HPV type (figure 3.10).
3.2.4 Validation of the detection assay for sensitivity
The sensitivity of the assay was assessed using cultured cervical
carcinoma cell lines with a known HPV DNA content. Test samples
consisted of serial dilutions of HeLa cells (containing 30-40 copies of
HPV 18 per cell) and SiHa cells (containing 1-2 copies of HPV 16 per
cell), mixed with 104 control Raji lymphoblastoid cells (without any
HPV)(Pater and Pater, 1985).
Using appropriate oligonucleotide primers for 35 cycles of the PCR,
amplified target DNA sequences were consistently detected by gel
electrophoresis from reactions containing 5 HeLa cells (data not shown)
or five SiHa cells (figure 3.11A). Quadruplicate reactions, nominally
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Figure 3.8
The specificity of HPV 33 primers to direct amplification by PCR of only
HPV 33 was tested using cloned HPV genomes as templates. This shows
agarose gel electrophoresis of the products of PCRs using HPV 33
primers with template plasmid DNA of types (a) HPV 6b, (b) HPV 11,
(c) HPV 16, (d) HPV 18 and (e) HPV 33. A lkb ladder marker track (M)
is included. Positive amplification is achieved only with HPV 33
template. Comparable results were achieved for the other HPV primer
pairs.
a b c d e M
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Figure 3.9
Amplified DNA from each of the HPV types was identified by restriction
enzyme mapping, with the sizes of digested DNA fragments determined
by agarose gel electrophoresis. A unique pattern of DNA fragments was
obtained for each HPV type/enzyme combination: (a) HPV6b/DdeI gave
133 and 104bp fragments; (b) HPV 11/DdeI gave 194 and 43 bp
fragments; (c) HPV 16/HinfI gave 200, 76 and 40bp fragments; (d) HPV
18/HinfI gave 81 and 63bp fragments; (e) HPV 33/DraI gave 79, 75 and
18 bp fragments. In some reactions small quantities of undigested




Dot blot showing HPV type-specificity of oligoprobe hybridisation to
amplified DNA. DNA was immobilised onto the nitrocellulose filter
undiluted and in ten- and one hundred-fold dilutions using PCR generated
amplified DNA from HPV types 6b, 11, 16 and 18 and acting as negative
and positive controls plasmid DNA of pBR322 (neg) and of HPV 11
(pos) respectively. The filter was hybridised with the biotinylated
oligoprobe for HPV 11 which was detected by a streptavidin and alkaline





Sensitivity of the assay is shown by agarose gel electrophoresis of
amplified viral DNA from SiHa cells directed by primers for HPV 16.
SiHa cells were serially diluted against a background of 10^ Raji cells.
(A) shows and reactions containing; no SiHa cells (c); 10^ SiHa cells (d);
100 SiHa cells (e); 10 SiHa cells (f) and 5 SiHa cells (g). (B) shows the
PCR products from several of the quadmplicate reactions; tracks (c-f) are
of reactions nominally containing 3 SiHa cells; tracks (g-j) are of
reactions nominally containing 4 SiHa cells. Included in both (A) and (B)
are lkb ladder tracks (M); positive control reactions of cloned HPV 16
plasmid DNA (a); and negative control template-free reactions (b).
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containing 4, 3, 2 or one SiHa cell were also analyzed. Two out of four
reactions containing three or four cells were positive and all of the
reactions containing one or two cells were negative (figure 3.1 IB). Thus,
the results demonstrate a threshold sensitivity of between 3 and 5 cells
(3-10 integrated HPV DNA copies).
3.3 Discussion
The assay was successfully applied to material from a variety of sources.
When amplified products were electrophoresed on an agarose gel
extracted DNA gave the least smearing, followed by frozen sections then
paraffin wax embedded sections. An accurate comparison of the
efficiency of PCR as applied to material from different sources was not
possible as this would have required the use of equivalent amounts of
differently processed material from the same case.
The HPV type specificity of detection assay described here was
demonstrated by amplification of HPV DNA only where primers were
used with template DNA of the appropriate type; the absence of
amplification where primers of one type were applied to template DNA
of another; confirmation of HPV type achieved by dot blot hybridisation
of amplified products with HPV type specific oligoprobes.
This specificity was achieved through design of separate primers and
probes with unique sequences for each HPV type. The length of primers
allowed use of a stringent annealing temperature reducing the probability
of illegitimate primer annealing to near complementary sequences. This
assay therefore could be seen to have an advantage over several in situ
hybridisation methods which cannot differentiate between HPV types 6
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and 11 (Schneider et al., 1991) and also some early PCR assays which
have been found to have problems arising from the cross amplification of
different HPV types (Syrjanen, 1990).
Other PCR based detection studies have used consensus or common
primers that bind to the DNA of a broad spectrum of HPV genotypes
(Snijders et al., 1990). In such studies specificity may be compromised
as low annealing temperatures (40°C) are required to allow the binding of
primers to a range of target sites not all of which are a perfect match.
Furthermore, it is worth noting that the use of separate type specific
primers will give precise data about HPV types of known oncogenic
potential whereas general primers will pick up other HPV types of
unknown potential.
The use of PCR amplification conferred high sensitivity upon the assay,
shown to be capable of detecting between 3-10 copies of HPV 16 in a
background of 10,000 sample cells. PCR is known to be more sensitive
than in situ hybridisation (which requires few cells and 20-800 HPV
genomes per cell depending on the assay), FISH (which requires few
cells and at least 10^ HPV genomes per cell), dot blot (which requires
500ng DNA and 1 HPV genome per cell) and Southern blotting (which
requires lOug DNA and 0.1 HPV genome per cell) in the detection of
HPV DNA (Syrjanen, 1990; Morris et al., 1990; Tham et al., 1991;
Arends, 1991).
Also, by siting primers for the PCR assay within the E6 gene both
episomal and integrated HPV can be detected whereas, other techniques
such as in situ hybridisation may require a high copy number per cell
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such as occurs in foci of replication of episomal viral DNA and may fail
to detect integrated HPV DNA which can be present at low copy number
(eg. SiHa contains 1-2 HPV copies/cell).
The use of a highly sensitive PCR assay for the detection of HPV DNA
requires the adoption of stringent precautions to avoid and detect
contamination by even trace quantities of HPV DNA from other sources
(Tidy and Farrell, 1989). These sources may include previously
processed pathological specimens, carryover of amplified DNA products
or aerosol formed from solutions of plasmids containing cloned HPV
DNA (Kwok et al, 1990). In order to reduce the incidence of false
positives anticontamination primers have been incorporated into some
assays (Van uen Brule et al., 1989). These primers spanned the HPV
cloning site and thus avoided detection of HPV plasmid DNA
contamination. However contamination from other sources would not be
detected using this approach. Furthermore, the siting of
anticontamination primers within the LI or El genes (cloning sites of
HPV 16 and HPV 18 respectively), which are often deleted or disrupted
following integration, could lead to false negatives if used alone.
The myocardial tissue and template-free negative controls used in this
assay should detect contamination from plasmid DNA, amplified
products and previously processed material occurring either during the
preparation of tissue for PCR, or the setting up of PCR. The precautions
taken to avoid contamination appear to have been adequate as no false
positives were detected since their adoption in over 500 PCR analyses.
The ability to detect trace amounts of DNA in clinical samples raises the
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question of their biological significance. The presence of trace amounts
of HPV DNA in non-neoplastic epithelium may be due to latent HPV
infection occurring, with little significant viral replication. Trace amounts
of HPV DNA found in CIN lesions or cervical carcinomas may
contribute to the neoplastic phenotype. Support for this possibility comes
from the fact that SiHa cells - derived from a cervical carcinoma- contain
only 1 to 2 copies of integrated HPV DNA of which E6 and E7 genes are
expressed (Pater and Pater, 1988). Thus it is possible that a single high
risk genome could contribute to a neoplastic phenotype. This being the
case its detection would require a highly sensitive assay .
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CHAPTER 4
DETECTION OF HPV IN CERVICAL NEOPLASIA
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4.1 Introduction
HPV is frequently found in carcinoma of the cervix and its precursor CIN^
supporting a role for the vims in cervical carcinogenesis. However the
precise involvement of HPV is not fully understood. Studies have shown
that HPV in co-operation with other factors has the potential to fully
transform human keratinocytes but it is not known where in the CIN-
cancer sequence HPV acts. Furthermore, while the levels of risk assigned
to HPV 6/11 and HPV 16/18 are widely accepted, there are conflicting
reports of an association between HPV 18 and glandular cervical
carcinoma and a more rapidly progressive type of carcinoma (Kurman et
al., 1988; Wilczynski et al., 1988; Griffin et al., 1991; Ji et al., 1991).
In this study, the highly sensitive and specific PCR based assay was
applied to cases covering the spectrum of cervical disease including
normal tissue, CIN, squamous and glandular carcinomas in order to
define more clearly their levels of association with specific HPV types. In
particular, this study aims to gain an understanding of the relationship
between HPV type and neoplastic aggression, between HPV type and
tumour differentiation and finally the stage or stages in the CIN-cancer
sequence at which HPV acts.
4.2 Cases Studied
The PCR assay as described in chapter 3 was applied to twenty four
control cases (mean age 35 , SD 11.29, range 17-56) , twenty cases each
of CIN I (mean age 30.3, SD 8.38, range 19-49), CIN 2 (mean age 28.65,
SD 7.43, range 19-45) and CIN 3 (mean age 31.4, SD 8.43, range 22-50),
as well as 26 cases of squamous cell carcinoma (mean age 36.6, SD
11.59, range 20-58) 16 cases of adenocarcinoma (mean age 39.7, SD
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7.48, range 28-58) and 4 cases of adenosquamous carcinoma (mean age
33.2, SD 5.85, range 26-40).
4.3 Results
All 24 normal control samples which consisted of frozen cervical tissue
taken at forensic autopsy were negative for HPV DNA. HPV DNA was
detected in 25% of CIN I cases, 60% CIN 2 cases, 60% CIN 3 cases and
in 80% of carcinomas. HPV DNA was detected in 75% of
adenocarcinomas, 81% of squamous carcinomas and all 4
adenosquamous carcinomas. The prevalence of individual HPV types in
these lesions reveals HPV 16 to be the most common in all grades of
lesion accounting for 60%, 75%, 92% and 62% of the total HPV positive
cases in CIN 1, CIN 2, CIN 3 and all carcinomas respectively (figure
4.1). No HPV 6b or 33 was identified in any of the cases examined. HPV
11 was found in only one lesion which was diagnosed as CIN 1. HPV 18
was found in 6 out of 26 (23%) cases of squamous carcinomas, 1 of 4
(25%) adenosquamous carcinomas and 7 of 16 (44%) glandular
carcinomas cases (figure 4.2). Two cases of adenocarcinoma contained
both HPV 16 and 18.
All cases found to be negative for the 5 HPV types by PCR were
subjected to amplification of a reference gene which produced amplified
DNA products of the appropriate size (figure 4.3), demonstrating that this
DNA was intact and that there was no inhibition of Taq polymerase in
these reactions. Amplified DNA taken from cases found to be HPV
positive from the PCR assay was subjected to dot blot hybridisation with
HPV type specific oligoprobes for confirmation of HPV type (figure 4.4).
71
Figure 4.1
Agarose gel electrophoresis of amplified DNA from cases of CIN using
frozen sections as template and primers for HPV 16 DNA. Eight cases
are positive (b-f, h, i, 1) and three cases are negative (g, j, k) for HPV 16.





Agarose gel electrophoresis of amplified DNA from cases of
adenocarcinoma using extracted DNA from paraffin wax-embedded
tissue as template and primers for HPV 18 DNA (c-1). Five cases are
positive and five cases are negative for HPV 18 DNA. Included are a
cloned HPV plasmid positive control track (a), a template free negative
control track (b) and a lkb ladder marker track (M).
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Figure 4.3
The presence of amplifiable DNA in clinical material was shown by PCR
amplification of a reference gene c-Ha-ras 1. Agarose gel electrophoresis
shows amplified DNA from nine normal control cases (c-k); a template
free negative control track (a); a cloned HPV plasmid DNA positive
control track (b) and lkb ladder marker track (M).
Mabcdef ghi j k
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Figure 4.4
Confirmation of HPV type by oligoprobe hybridisation of PCR products.
(A) shows the PCR products from three cases of adenocarcinoma (a-c)
and two cases of squamous carcinoma (d, e) undiluted, and diluted ten-
and one hundred-fold detected with a biotinylated HPV 16 oligoprobe.
(B) shows PCR products from 4 cases of adenocarcinoma (f, g, i, j) and
one case of adenosquamous carcinoma (h) undiluted and diluted ten- and
one hundred-fold, detected with a biotinylated HPV 18 oligoprobe. Both
(A) and (B) include a positive control of amplified cloned HPV plasmid
DNA undiluted and diluted ten- and one hundred-fold (P) and a negative
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The results for HPV prevalence in adenocarcinomas were adjusted to
exclude cases which contained adjacent CIN (table 4.5). Eleven of the
sixteen cases examined contained no adjacent CIN. Eight of these eleven
cases (73%) contained HPV DNA , five (45%) contained HPV 18 and
four (36%) contained HPV 16 (one case contained both HPV 16 and 18).
There was no significant difference in the mean ages or proportion of
cases over 35 years of age between HPV containing cases and those
found to contain no HPV DNA of types 6, 11, 16, 18 or 33 (X2 test). To
compare the effects of HPV 16 and HPV 18 on neoplastic progression
various CANCER/CIN prevalence ratios were calculated (table 4.6).
These show a 1.9 - 2.8 fold difference between virus types.
The HPV prevalence data from 130 samples of cervical tissue are
summarised in table 4.7. The statistical significance (X2) of comparative
HPV prevalence in normal tissue, CIN 1, CIN 2/3, squamous carcinoma
and adenocarcinoma is summarised in table 4.8.
4.4 Discussion
No HPV DNA was found in any of the 24 control cervices from forensic
autopsy. These negative results contrast with HPV prevalence figures of
between 0 and 70% from studies using PCR based methods (Young et
al., 1989; Manos et al., 1990) and between 9 and 19.5 % using non-PCR
based methods (deVilliers et al., 1987; Wickenden et al., 1987). These
widely differing rates may be attributable to several factors including, the
varying sensitivity of each particular detection assay, the source of the
control population, or the different cervical sampling methods used. The
different sensitivities of the commonly used detection methods have
been widely reported (Munoz et al., 1988; Melchers et al., 1989; Tham et
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Table 4.5
Overall prevalence of HPV DNA in glandular carcinomas with adjacent







CIN 8 (73%) 3 (27%) 1 1
TOTAL 12 (75%) 4 (25%) 16
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Table 4.6
CANCER/CIN prevalence ratios for HPV 16 and 18.
Prevalence Ratio HPV 16 HPV 18
18/16
Ratio
All Cancer: All CIN 1.42 3.75 2.6
Squamous cancer: All CIN 1.5 2.87 1.9
All Cancer: CIN 2/3 1.08 3 2.8
Squamous Cancer: CIN 2/3 1.1 2.3 2.1
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Table 4.7
The frequency of HPV 6b, 11, 16, 18 and 33 DNA in normal tissue and
cases of CIN 1, CIN 2, CIN 3, squamous carcinoma, adenocarcinoma and
adenosquamous carcinoma by PCR.
DIAGNOSIS N




6 11 16 18 33
CONTROLS 24 - - - - - -
CIN 1 20 - 1 (5) 3 (15) 1 (5) - 5 (25)
CIN 2 20 - - 9 (45) 3 (15) - 12 (60)
CIN 3 20 - - 11 (55) 1 (5) - 12 (60)
SqCa 26 - - 15 (58) 6 (23) - 21 (81)
AdCa 16 - - 7 (44) 7 (44) - 12 (75)"
AdSqCa 4 - - 3 (75) 1 (25) - 4 (100)
a. 2 cases positive for both HPV 16 and 18.
79
Table 4.8
P values of the X2 statistic (DF=1) for the comparison of overall HPV
prevalence in normal tissue, CIN 1, CIN 2/3, squamous carcinoma and
adenocarcinoma.
CIN 1 CIN 2/3 Sq Ca Ad Ca
Controls <0.001 <0.001 <0.001 <0.001
CIN 1 <0.001 <0.001 <0.001
CIN 2/3 <0.1 <0.01
Sq Ca <0.5
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al., 1991). While the insensitive FISH and dot blot techniques may
underestimate HPV prevalence, the contamination often associated with
PCR based methods may result in false positives and an overestimate of
HPV prevalence. The method used here was validated for sensitivity and
incorporated negative controls designed to detect contamination.
The source of the control population examined in many studies has
included patients attending sexually transmitted disease clinics, patients
successfully treated for CIN and patients attending colposcopy clinics,
arguably unrepresentative of the normal population. In support of this, a
recent study compared HPV prevalence in two different groups of
women; a symptom free population involved in a district call scheme for
cervical cancer and gynecological outpatients population containing
women visiting the clinic for a wide range of gynecological complaints
or for control of hormonal contraception. HPV prevalence in the latter
group ranged from 9.2% to 21.5% depending on whether patients had a
history of cervical pathology. This was significantly higher than the figure
of 3.5% for HPV prevalence in the symptom-free group (van den Bmle et
al., 1991). The cervical tissue used in the present study came from young
women undergoing forensic autopsy following accidental death. This is
arguably an apparently random sample more representative of the normal
population.
It has been suggested that the different cervical sampling methods used in
HPV prevalence studies may account for the varying results (Munoz et
al., 1988). Commonly used methods include the cervical scrape and
lavage which sample a large area of exocervical epithelium consisting
largely of superficial cells. Here, histologically normal full thickness
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epithelium was taken from the cervical transformation zone.
The comparison of HPV prevalence in CIN lesions found in different
studies proves difficult because of the different detection methods used
and the manner in which results are presented (that is figures for HPY 6
and 11 or CIN 1 and CIN 2 are often combined). The finding of HPV in
60% of CIN 2 lesions is higher than previously reported for CIN 2
biopsies as analyzed by dot blot whereas the finding of HPV in 60% of
CIN 3 is lower than reported for CIN 3 biopsies in other studies (Pater et
al., 1986). The prevalence of HPV in CIN 1 and CIN 3 biopsies in this
study is not as high as in other studies using scrapes (Melchers et al.,
1989). These differences may relate to the focussed sampling of punch
biopsies on the abnormal region, compared with the widespread sampling
of scrapes, which may include distinct regions of viral replication not
necessarily relevant to a particular CIN lesion.
The figure of 81% for HPV prevalence in squamous carcinoma is in
broad agreement with the findings of several other groups using PCR
detection assays, whereas the finding of HPV types 16 and 18 in 75% of
the 16 adenocarcinomas used in this study is considerably higher than
reported in some recent studies (Griffin et al., 1991, Young et al., 1991).
One of these studies found no HPV DNA of types 6, 11, 16 or 18 in 21
cases of adenocarcinoma (Young et al., 1991). One explanation for this
low HPV prevalence may be the detection method used - in situ
hybridisation (ISH) - which is of very low sensitivity compared with PCR
(Levi et al., 1989). In support of this, a study using both ISH and PCR to
detect HPV DNA in cervical adenocarcinomas found only one of five
cases giving a positive PCR result also gave a positive ISH signal
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(Griffin et al., 1991). Griffin et al detected HPV types 16 and 18 in only
31% of glandular cancers. While this assay was carefully validated for
both specificity and sensitivity, several alternative explanations were
offered by the authors for the low frequency of HPV detected as
compared with previous studies. These included possible geographical
differences in HPV carriage given the study in question came from the
UK whereas many of the previous studies originate from the US or
Australia; the existence of one population of adenocarcinoma occurring
in young women (under 35 years of age) which is related to HPV
infection and another in older women which is not associated with a
sexually transmitted agent; contamination by adjacent CIN (a possibility
also suggested by Young et al (1991) to explain the low detection rate in
their study).
Contamination by adjacent CIN and the possibilty of age distribution can
be excluded as explanations for the high prevalence of HPV in
adenocarcinomas presented here. Both the high sensitivity of the assay
and the check for amplifiable DNA in all PCR negative cases, minimised
the possibility of false negatives.
It is possible that the low prevalence of HPV detected by Griffin et al
(1991) in paraffin wax embedded adenocarcinomas may be due to a lack
of DNA amplifiable by PCR. The importance of a check for amplifiable
DNA should not be underestimated, especially in view of recent studies
which highlight the possible occurence of false negatives when using
PCR on paraffin wax derived tissue. In one study it was found that the
amount of PCR product varied inversely with the number of tissue
sections used. The authors' attempts to remove this "PCR inhibition" by
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various treatments which included extensive deparaffinisation and
proteinase K digestion were unsuccessful (Lo et al., 1989). It has also
been found that amplification of extracted digested samples which have
been stored is not as successful as is amplification of samples that have
been used immediately after digestion (Wright and Manos, 1990).
Prevalence of individual HPV types found in the present study supports
the findings of previous studies in that HPV 6/11 are confined to low
grade CIN lesions whereas HPV types 16 and 18 are seen with increasing
frequency through the spectrum of cervical neoplasia (figure 4.9)
supporting a role for these types in the development of cervical
carcinoma (Lorincz et al., 1987; Kurman et al., 1988). However, the
results of this study emphasise the biological similarity between CIN 2
and CIN 3 and their divergence from CIN 1 as regards HPV prevalence.
This finding suggests that CIN 1 lesions may be induced by factors
other than HPV infection and thus only CIN 2/3 are the tme precursors
to invasive cancer. In the CIN-cancer sequence HPV 16 and 18 could be
seen as effecting transition from normal tissue or CIN 1 to the CIN 2/3
state.
It seems likely that the presence of HPV 16 or 18 in CIN lesions may
indicate a greater tendency for progression and thus, data on HPV may
prove to be of use in an improved diagnostic and prognostic system for
classification of CIN, possibly leading to the more regular screening or
earlier treatment of women where these vims types are detected. The
decision whether or not to treat CIN 1 lesions, many of which have been
found to regress, appears to be a difficult one (Syrjanen et al., 1987).
Prospective clinical and viral studies aimed at delineating long term
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Figure 4.9
Bar chart of the prevalence of HPV 11 and HPV 16/18 in 24 controls and
20 cases each of CIN 1, CIN 2 and CIN 3 and 46 cases of carcinoma.
HZ] HPV 6 or 11 YZ2\ HPV 16 or 18
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behaviour of low and moderate grade CIN lesions based on HPV type
may help to establish this as a valuable prognostic indicator.
It has been suggested that there are differences in behaviour of tumours
associated with HPV types 16 and 18. HPV 18 has been reported as being
more prevalent in glandular carcinoma of the cervix and having a greater
tendency toward rapid progression to cervical cancer.
Interestingly, the results of this study show significantly more HPV 16 in
squamous carcinomas (58%) than HPV 18 (23%)(P<0.001; X2 test) but
identical frequency in glandular cancers (44%)(figure 4.10). Similar
results were reported by Tase et al (1988) using ISH, HPV 18 was found
in 40% of adenocarcinomas and in none of the squamous carcinomas
whereas HPV 16 was found in 54% of squamous carcinomas and in one
of forty adenocarcinomas; and also Wilcynski et al (1988) using Southern
blotting, found 50% HPV 16 and 7% HPV 18 in squamous carcinomas
and 13% HPV 16 and 50% HPV 18 in adenocarcinomas.
Cervical squamous carcinomas are more common and have a better
prognosis than adenocarcinomas (Buckley and Fox, 1989). The
association of squamous carcinoma with more HPV 16 than HPV 18
compared with equivalent frequency of the two types in adenocarcinoma
suggests that HPV 16 confers a better prognosis in terms of cancer cell
differentiation, than HPV 18.
To determine whether the presence of HPV 18 could be associated with
mucin production by associated tumours, (an indicator of glandular
differentiation) AB/PAS stains were carried out on all cases of
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Figure 4.10
Bar chart comparing the relative prevalence of HPV 16 and HPV 18 in
glandular and squamous carcinomas.
HPV 16 7ZZ HPV 18 CZJ HPV 16 and 18
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carcinoma. No correlation was found.
While the reasons for the differences in prevalence of HPV 16 and 18 in
cervical adenocarcinomas and squamous carcinomas requires further
investigation, two models are postulated. Different HPV types may target
different cell populations already committed to either glandular or
squamous differentiation. Alternatively, HPV infection may affect
epithelial cell differentiation such that HPV 18 tends to induce glandular
differentiation, whereas HPV 16 may tend to induce squamous
differentiation.
The high prevalence of HPV 16 and 18 in glandular carcinomas may
indicate a role for particular viral types in neoplastic progression and it is
possible that data on HPV type infection in smears may be useful in
detecting the presence of glandular atypia or adenocarcinoma in situ
(AIS) since the sensitivity of the Pap smear in detecting preinvasive
glandular neoplasms of the cervix appears to be suboptimal.
To investigate the possibility that HPV 18 may have a greater tendency
toward rapid neoplastic progression than HPV 16, four CANCER/CIN
ratios were calculated for each HPV type. While CIN is believed to be a
precursor of squamous carcinoma it is unclear whether adenocarcinoma
can also develop from CIN or whether glandular atypia or AIS can
progress to squamous carcinoma. For this reason ratios were calculated
both from data for all carcinomas and for squamous carcinomas alone.
Ratios were calculated from data for all CIN combined and also for CIN
2/3 (which may represent the true precursors of cervical cancer). The
amalgamation of HPV prevalence figures for CIN lesions can be justified
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as stages one to three are arbitrary divisions in a morphological
continuum. The ratios range from 2.3-3.75 for HPV 18 and from 1.08-1.5
for HPV 16 representing a 1.9-2.8 fold difference between vims types
suggesting a role for HPV 18 in either a greater risk of progression or a
more rapid transition to malignancy. Similarly, Kurman et al (1988)
reported a CANCER/CIN ratio of 7.3 for HPV 18 and 1.1 for HPV 16 (a
6.6 fold difference). Thus, from both the comparison of HPV types
associated with cancer cell differentiation and CANCER/CIN prevalence
ratios it would appear that HPV 18 is more aggressive than HPV 16.
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CHAPTER 5
DETECTION OF LARGE SCALE SEQUENCE
ALTERATIONS IN THE HPV URR
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5.1 Introduction
The results of this and many other studies support a role for HPV in
cervical neoplasi&However7 there are thought to be other events or factors
required for progression to invasive carcinoma. Integration of viral DNA
into the host genome may produce an altered pattern of viral gene
expression contributing to the neoplastic process. HPV variants with
deletion or duplication of URR sequences may have a similar effect.
The common HPV types have been shown to have different oncogenic
potentials and these are reflected in their immortalization properties. HPV
18 has been associated with a more aggressive or rapidly progressive type
of cervical carcinoma. Interestingly, recent studies have found that the 10
to 50 fold greater immortalization efficiency of HPV 18 as compared to
HPV 16 maps to the upstream regulatory region (URR) indicating a
possibility that differences in URR sequence may in part account for the
different oncogenic potentials associated with particular HPV types
(Romanczuk et al., 1991; Villa and Schlegel, 1991). The URR differs
between different HPV types while retaining its regulatory functions for
viral DNA replication and gene expression (Chong et al., 1990). It is
conceivable therefore that different URR sequences will give rise to
subtly different patterns of gene expression some of which may affect
the neoplastic process.
The results of several studies have indicated a high degree of URR
sequence divergence within HPV types (Deau et al., 1991; Chan et al.,
1992). HPV variants with alterations to the URR have been discovered in
a variety of genital cancers and unusual lesions (table 5.1, figure 5.2). It
has been suggested that pathogenicity of these HPV variants may be
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Table 5.1
Several HPV variants are shown including, the major duplications (+) or
deletions (-) and their position in the HPV genome. The lesions from
which these subtypes were first isolated and appropriate references are
also shown.
VARIANT +/- POSITION
OF + /- SEQ
LESION REFERENCE
6ma + 7681 - 7836 conyloma of nipple Kulke et al., 1989
6vc + 7302 - 7363 vulvar carcinoma Rando et al., 1987
6d + 7528 - 84 Buschke-Lowenstein tumour Boshart & zur Hausen.1986
6-T70 + 7300 - 7323 vulvar carcinoma Kasher & Roman, 1988
6-T70 ♦ 7303 - 7356 vulvar carcinoma Kasher & Roman, 1988
6-T70 - 7351 - 7399 vulvar carcinoma Kasher & Roman, 1988
11v + 6090 - 374 lung carcinoma metastasis Byrne et al., 1987
16v - 7598 - 17 cervica' carcinoma Tidy et al., 1989
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Figure 5.2
Diagrammatic representation of the sequence alterations located in the
URR of several HPV variants, shown in relation to the putative viral
enhancer and promoter elements. Deletions and duplications are
represented by solid and shaded boxes respectively.








influenced as a result of the deletion and/or duplication of sequences
encompassing some of the putative control elements for viral gene
expression.
The discovery in genital cancers of HPV 6 and 11 variants with
alterations to the URR supports the view that duplication or deletion of
URR sequences may be sufficient to confer a higher oncogenic potential
on a vims normally associated with low grade lesions (Boshart and zur
Hausen, 1986; Rando et al., 1986; Byrne et al., 1987; Kasher and
Roman., 1988). Variants of HPV 16 have been found in a variety of
lesions, including genital carcinomas. One study, using Southern blotting,
found the same HPV 16 URR deletion variant in two independently
derived cervical carcinomas inferring that the deleted HPV 16 is a
transmissible variant (Tidy et al., 1989).
Despite the increasing number of variants being reported and the recent
evidence to suggest that they may be transmissible very little is known
about their prevalence in cervical lesions with many having come to light
as a result of detection assays using PCR or Southern Blotting. In this
systematic survey a PCR based assay was specifically designed to detect
sequence alterations within the URRs of HPV types 16 and 18 from
cervical lesions. The correlation of particular URR sequence alterations
with the grade of lesion may offer an explanation as to why some cases
of HPV 16 and 18 progress and others persist or regress.
5.2 Assay design
A PCR assay was designed to amplify the entire URR in four contiguous
segments (figure 5.3). Small deletions or insertions within the region
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Figure 5.3
Arrangement of primer pairs for amplification of segments A-D of HPV
16 and HPV 18. Segments are shown in relation to their location in the
HPV genome. Segment A primer 1 sites lie within the LI gene. Segment
D primer 2 sites lie within the E6 gene. All other primer sites lie within
the URR. In the URR, E denotes the E2 binding sites and P the promoter









would be seen as a deviation in length from the prototype segment of
cloned HPV plasmid DNA when amplified PCR products were
electrophoresed on an agarose gel. In order to amplify the URR in four
contiguous segments, sequences of the URR and flanking sequences of
the LI and E6 genes of HPV types 16 and 18 were searched for five sites
that were approximately evenly spaced and suitable for efficient primers.
The number of possible sites was limited owing to the abundance in the
URR of unusual sequences - such as those of the AT/GT rich region,
likely to have unusual secondary structure - and repeated sequences such
as that of the E2 binding palindrome ACC^GGT.
Eight oligonucleotide primers were chosen for each HPV type (16 and
18) using UW programs, and were checked for any significant secondary
structure, cross hybridisation and 3' complementarity using the approach
described in Chapter 3. The %GC content for HPV 16 primers was
between 23% and 57%, and for HPV 18 primers between 38% and 65%.
Primers chosen were between 20-26 bases in length permitting the use of
high PCR annealing temperatures and improving specificity by reducing
the incidence of illegitimate binding of primers to near complementary
sequences. Primer sequences chosen along with their locations in the
HPV genome are detailed in table 5.4.
The PCR assay was optimized for each primer pair using cloned HPV
plasmid DNA and an initial primer annealing temperature of 42°C. The
optimum annealing temperature was considered to be the highest
temperature to allow amplification without reducing the yield of specific
amplified product. The optimum temperatures are detailed in table 5.4.
Step times for denaturation, primer annealing and extension were varied
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Table 5.4
Nucleotide sequence (5' to 3') of the pairs of PCR primers for segments
A-D of HPV 16 and HPV 18, their position within the HPV genome
according to the EMBL database nomenclature, the lengths of amplified
products, optimum annealing temperatures. HPV 16 primer 2(ii) was
suitable for use on frozen material, cloned HPV plasmid DNA and DNA
extracted from paraffin wax embedded material whereas HPV 16 primer
2 was unsuitable for use on DNA extracted from paraffin wax embedded
material.
HPV SEG P SEQUENCE (5' to 3') POSITION
PRODUCT
LENGTH Ta (oC)
16 A 1 CCT CTA CAA CTG CTA AAC GC 7117-7136
272 50
16 A 2 GTA GCA AAT ATA GTT TAT ATA C 7368-7389
16 B 1 GTA TAT AAA CTA TAT TTG CTA C 7368-7389 219 46
16 B 2 GAA TGG TTG GCA AGC AGT GCA GG 7564-7586
16 B 2(ii) CAA GCA GTG CAG GTC AGG AAA AC 7574-7596 228 46
16 C 1 CCT GCA CTG CTT GCC AAC CAT TC 7564-7586 297 50
16 C 2 CGG TTT GCA CAC ACC CAT GTG CAG 7837-7860
16 D 1 CTG CAC ATG GGT GTG TGC AAA CCG 7837-7860 213 50
16 D 2 CTG TGG TAA CTT TCT GGG TCG CTC C 121-145
18 A 1 GCC AAG CGT GTG CGT GTA CG 7104-7123 234 46
18 A 2 CAG TTG TTA CTC ACT AGC CG 7318-7337
18 B 1 GCC CTA GTG AGT AAC AAC TG 7318-7337 249 46
18 B 2 GTT CAA AAT AGT TAG GAC CAG 7546-7566
18 C 1 CTG CTC CTA CAT ATT TTG AAC 7546-7566 228 50
18 C 2 GGG ATG ACA GAA TGT TGG AC 7754-7773
18 D 1 GTC CAA CAT TCT GTC TAC CC 7754-7773
22 1 50
18 D 2 CAA AGC GCG CCA TAG TAT TG 98-117
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to find the optimum which was 1 min, 2 min, 3 min respectively. Each
primer pair generated a fragment of predicted length from cloned HPV
DNA (figure 5.5).
In order to achieve optimal separation of amplified products guidelines
suggested by Thivierge (1989) were taken into account. Amplified
products were electrophoresed on 4% agarose gels (3% Nusieve GTG:
1% Seakem GTG) for segments A-D and on 1% agarose gels (Seakem
GTG) for the entire URR, for 8-1Oh at 100mA along with a DNA size
marker (Mspl digest of pBR322, Biolabs or lkb ladder, Gibco-BRL). The
length of the electrophoretic gel, the grade of agarose and the DNA size
marker were such that sequence alterations (duplications or deletions) in
segments A-D of between 10-20 bp in length should have been detectable
as indicated by clear separation of 142/154 and 200/220 bp fragments of
the lkb ladder.
The assay was applied to 2 cases of CIN 1, 12 of CIN 2 and 10 cases of
CIN 3 (all frozen material which was used directly without DNA
extraction), in addition to, 20 cases of squamous cell carcinoma, 11 cases
of adenocarcinoma and 3 adenosquamous carcinomas, processed as
paraffin blocks and subjected to DNA extraction as described in Chapter
2. All cases used in the assay had been found to contain HPV DNA of
types 16 or 18 in the PCR detection assay described in Chapters 3 and 4.
5.3 Results
In a total of 24 cases of CIN and 34 cases of cervical carcinoma no




Agarose gel electrophoresis of amplified DNA using cloned HPV
plasmid DNA as template and primers pairs for HPY 16 (a) segment A
(fragment length 272bp); (b) segment B (228bp); (c) segment C (297bp);
(d) segment D (213bp); and HPV 18 (e) segment A (234bp); (f) segment
B (249bp); (g) segment C (228bp); (h) segment D (221bp).
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Figure 5.6
Agarose gel electrophoresis of amplified DNA from 7 cases of CIN using
frozen sections as a template and PCR primers for HPV 16 segment A (a-
g; band B). Included are a cloned HPV plasmid DNA positive control
track (P), a template free negative control track (N) and a Mspl digest of
pBR322 DNA marker track (M). Additional bands visible on the gel (A,
C-E) are believed to be "ghost bands" arising from non-specific annealing




Agarose gel electrophoresis of amplified DNA from cases of squamous
carcinoma (a-f) using extracted DNA from paraffin wax embedded tissue
as template and primers for HPV 16 segment A (1), B (2), C (3), D (4)
and HPV 18 segment A (5), B (6), C (7) and D (8). Included are template
free negative control tracks (N), cloned HPV plasmid DNA positive
control tracks (P) and lkb or Mspl digest of pBR322 marker tracks (M)
101
102
When the assay was applied directly to frozen material, PCR artefacts
known as "ghost bands" - which can occur as a result of non specific
primer annealing to near complementary sequences - were identified on
the agarose gels (figures 5.6). In an attempt to reduce the incidence of
these ghost bands; step times for primer annealing and extension were
reduced. These measures were unsuccessful. Raising the annealing
temperature is often a useful way of improving PCR stringency however
the Ta was already as high as primer-target binding stringency would
allow. Cervical biopsies were too small to permit the use of DNA
extraction procedures. To alleviate this problem, HPV DNA of frozen
cases was subjected to additional amplification of the entire URR in one
segment (figure 5.8) to look for any large sequence alterations, which
could be mistakenly identified as ghost bands, prior to amplification of
the URR in four segments.
When the assay was applied to extracted DNA from paraffin wax
embedded tissue no ghost bands were generated (figures 5.7.1-8),
however the primers for HPV 16 segment B (figure 5.3) produced only
"primer dimer" PCR artefacts when reaction products were
electrophoresed on an agarose gel. To determine which primer was
inefficient two PCR reactions were set up: one using segment A primer 1
with segment B primer 2; another using segment C primer 2 with
segment B primer 1. Only the latter combination generated an amplified
product of predicted length indicating a problem with segment B primer
2. A reaction set up using segment B primers and a lower annealing
temperature - as primer sequences were both short and had a low GC
content - failed to generate an amplified product of predicted length. A
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Figure 5.8
Agarose gel electrophoresis of amplified DNA from three cases of CIN
(b-d) using frozen tissue as template and HPV 16 segment A primer 1
with HPV 16 segment D primer 2 (spanning the entire HPV URR).




new primer 2 for segment B was therefore designed and successfully
applied to DNA extracted from paraffin wax embedded tissue (seg B,
primer 2;ii, table 5.4).
The HPV type specificity of the assay was apparent when applied to a
case of double infection (found to contain both HPV 16 and HPV 18). No
additional bands were generated when primers for one HPV type were
applied to cases containing both HPV types despite differing product
lengths of equivalent segments from each HPV type (table 5.4).
5.4 Discussion
It is possible that the oncogenic potential of individual HPVs could be
influenced by sequence alterations within the URR. While there have
been several reports of the existence of naturally occurring HPV URR
mutants isolated from a range of genital lesions little is known of their
overall prevalence in cervical lesions. In this study, a PCR based assay
was designed specifically to look for sequence alterations within the HPV
URR which might influence oncogenic potential and thus contribute to
neoplastic progression.
The assay was applied to material from different sources - both frozen
material and DNA extracted from paraffin wax embedded tissue. When
applied directly to frozen tissue (24 cases of CIN), gel electrophoresis of
amplified products showed not only bands of expected length but often
several additional bands (figure 5.6). These were judged to be ghost
bands (which arise due to non-specific primer annealing), as opposed to
true sequence alterations, on the basis of several observations. (1) The
additional bands seen in sample tracks were in some instances seen also
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in the plasmid control track and therefore were not considered to be
deviations from prototype (figure 5.6 (A)). (2) Identical additional bands
were seen in many and often all sample tracks (figure 5.6(C, D, E)).
While it is possible that these represented very common deviations
previous reports would indicate this to be unlikely. (3) Additional
fragments at least lOObp longer than predicted fragment length were not
found to be congment with any sequence alterations found when the
entire URR was amplified in one segment (figure 5.6(C, D, E). (4) In
every case the most abundant fragment was that of predicted length
(figure 5.6(B)).
The abundance of ghost bands in this assay as compared to the
previously described detection assay when applied directly to frozen
tissue may be due to the shorter primers used in the URR assay. Shorter
primers require lower annealing temperatures and thus the specificity of
the assay is reduced. The length of the primers for the URR assay was
restricted owing to the abundance of unusual sequences within this region
making it difficult to find sequences long enough to minimise ghost band
formation.
While it is possible that these additional bands may represent sequence
duplications within the URR it was thought to be unlikely. The matter
could have clarified by Southern hybridisation of the agarose gels using
an HPV type and segment specific oligoprobe probe which would not
hybridise to illegitimately amplified genomic sequences.
When the assay was applied to extracted DNA from paraffin wax
embedded cervical carcinomas one primer pair failed to generate a band
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of expected length in any of the cases examined. One additional fragment
approximately the length of the two primers suggestive of a primer dimer
PCR artefact was generated. Conditions thought to favour the formation
of primer dimers include 3' complementarity between primer pairs, or
high primer concentration or low starting template DNA concentration.
Had primer or template DNA concentration been the problem a similar
result using other primer pairs would be expected and this was not the
case. Also there was no obvious complementarity between the 3' ends of
primers. The failure of previously effective primer pairs when applied to
DNA extracted from paraffin wax embedded tissue has been observed by
other investigators within our laboratory.
The design of a PCR based assay to detect large scale sequence
alterations allowed a large number of isolates to be screened in a
relatively short time whereas, the detection of point mutations would
have required the use of more lengthy procedures such as asymptomatic
PCR and sequencing. Moreover, while point mutations may affect the
oncogenic potential of a vims it is easier to speculate as to the possible
effects on pathogenicity conferred by the loss or duplication of putative
enhancer and promoter sequences such as those of HPV 16v or HPV 6vc.
There have been, as yet, no reports of HPV 18 viral variants thus it is not
surprising that no URR mutants were found in the 16 cases containing
HPV 18. The negative results for URR mutants in 43 cases containing
HPV 16 compares favourably with the findings of a recent study aimed at
looking for sequence alterations in the 3' portion of the HPV 16 URR
(Chan et al., 1992). In a total of 118 cases of HPV 16 (90 of which were
isolated from cervical lesions and smears) only 38 variants were found.
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Most of these variants differed by one or several point mutations. It
would appear from these results that large sequence duplications or
deletions may not be widespread in cervical lesions, however their
existence may offer an explanation as to how low risk or episomal HPVs
may contribute to the neoplastic process.
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CHAPTER 6
DESIGN OF A PCR BASED ASSAY TO DETERMINE




HPV 16 and 18 have been categorised as high risk HPV types on the
basis of their prevalence in high grade CIN and cervical cancers as found
by others and in chapter 4 of this study and it has been suggested that the
presence of these HPV types in cervical lesions may indicate a greater
tendency for progression to invasive carcinoma (Lorincz et al., 1987).
However, not all lesions containing HPV of types 16 or 18 develop into
invasive cancers and it is thought that additional events are required for
neoplastic progression. The results of chapter 5 of this study indicate that
URR sequence alterations are rare and are therefore unlikely to be useful
indicators of those HPV-containing lesions most likely to progress to
invasive carcinoma.
The integration of HPV DNA into the host genome has been proposed as
an important event in neoplastic progression. The regular pattern of
interruption of viral E2 or El genes resulting from the integration event
dismpts the negative transcriptional control of E6 and E7 transforming
genes by the E2 gene products leading to their continuous or high level
expression possibly promoting the development of cancer (Arends et al.,
1990).
In support of this, HPV DNA has been found integrated into the host
genome in many cervical cancers (Lehn et al., 1985; Durst et al., 1985),
in carcinoma-derived cell lines (Yee et al., 1985) and experimentally
immortalized human keratinocytes (Barbosa and Schlegel, 1989;
Woodworth et al., 1989). In benign productive infections the vims is
maintained as an episome. Several studies have shown the presence of
integrated HPV DNA in some CIN lesions, although there appears to be
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little agreement on the stage in the CIN-cancer sequence at which
integration occurs. One study of HPV containing CIN lesions and
cervical carcinomas found HPV DNA to be episomal in all CIN 1 lesions
and integrated in only 5% of CIN 2 and CIN 3 lesions as compared with
81% of carcinomas (Cullen et al., 1991). A study by Lehn et al (1988)
found only episomal HPV DNA in CIN 1 lesions whereas 91% of the
CIN 2 and CIN 3 lesions contained integrated HPV DNA. Further
investigation of the physical state of HPV DNA in CIN and cervical
carcinomas is required to determine when integration occurs and whether
it indicates a greater likelihood for progression to invasive carcinoma
establishing its role as a useful prognostic indicator.
Non-isotopic in situ hybridisation has been used by some investigators to
distinguish between episomal and integrated HPV DNA (Cooper et al.,
1991). However, this method relies on subjective interpretation of
different staining signal types. The experimental approach employed by
most investigators to determine the physical state of HPV DNA in
clinical samples is that of restriction enzyme mapping with subsequent
Southern blot hybridisation. In cases where the results from these
techniques are difficult to interpret two-dimensional gel electrophoresis is
often used as a confirmatory measure. One drawback of these techniques
is that they require large amounts fresh tissue from which to extract
DNA. Many CIN 2 and CIN 3 lesions affect only small regions of
cervical epithelium. PCR detection of HPV DNA can be applied to small
clinical samples but presently used assays cannot differentiate between
integrated and episomal HPV DNA.
In this study, an anchor PCR (A-PCR) based assay was designed and
in
developed for use in determining the physical state of HPV 16 DNA in
small samples of cervical lesions. The assay was aimed at distinguishing
the integrated form of HPV DNA from the episomal monomelic and
multimeric forms. Episomal multimers can occur as head to tail repeats
which may be intact or show deletions and duplications (Choo et
al.,1989; di Luca et al., 1989). Although relatively uncommon, episomal
multimers can complicate the interpretation of restriction enzyme patterns
from integration assays based on Southern blotting (Cullen et al., 1991).
Some lesions may have combinations of integrated and episomal forms.
6.2 Assay Design
The assay can be divided into two separate stages: initial PCR analysis to
detect the presence of the entire viral genome using standard procedures,
followed by an A-PCR based analysis developed specifically for
discriminating between integrated and episomal HPV DNA.
6.2.1 PCR Analysis
For the primary analysis, PCR is used to amplify the entire HPV genome
in eight contiguous segments (A-H, fig 6.1), each of approximately lkb
in length. Amplified products are electrophoresed on 1% agarose gels and
the results interpreted as follows. If only integrated HPV DNA is
present, at most seven of the eight reactions (and possibly fewer) will
result in amplified products of expected length. This being the case the
site of integration in the non-amplifiable segment could be confirmed by
subsequent A-PCR analysis applied to that segment (see below). If an
irregular multimer (with deletions or duplications) was present, PCR
amplification would be likely to generate some additional fragments of
unexpected length. This could be confirmed by Southern blotting using
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Figure 6.1
Segments A-H of HPV 16 shown in relation to the viral ORFs. A suitable
A-PCR restriction site is shown for each segment.
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specific oligoprobes from each of the segments of the HPV genome, or
by cloning and sequencing amplified fragments. If episomal (monomer
or intact multimer) HPV DNA is present a fragment of predicted length
for each segment A-H will be generated. This may mask any integrated
HPV DNA which might be present within the same clinical sample.
Thus, any such case found to contain episomal HPV DNA would be
subjected to A-PCR for each segment A-H (see below).
6.2.2 Anchor-PCR Analysis
A modified Anchor-PCR method can be used to engineer a primer site
(p-adapt) at a known restriction enzyme cutting site and allow
amplification between the restriction site and a known specific primer site
(p-spec). This allows amplification of a viral-host DNA junction when a
virus integrates randomly within the host genome because a p-spec site is
always available within the integrated viral genome.
Template DNA is digested with an appropriate restriction enzyme (see
below) and 3' ends are tailed with dATP (figure 6.2). PCR amplification
is subsequently achieved by virtue of three primers: a viral sequence
specific primer (p-spec), a unique sequence 22 base primer (p-adapt) and
a hybrid primer consisting of oligo-dT (17 T nucleotides) linked to the
adapter primer (p-T-adapt). The hybrid primer (p-T-adapt) anneals to the
3' poly A tail. This is required for the initial cycles of amplification.
Subsequent cycles of amplification can be achieved using the adapter
primer (p-adapt) and gene specific primer (p-spec). As the hybrid primer
(p-T-adapt) is only needed for the start of the reaction, it is used at a
lower concentration than the other two primers.
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Figure 6.2
Schematic representation of the A-PCR protocol. PCR amplification is
achieved through use of three primers p-spec, p-T-adapt and p-adapt.
Only one of the original DNA strands (the positive strand in this
example) is amplified.

























This anchor-PCR analysis is used to investigate which particular
segments of the HPV genome (A- H) are disrupted by integration. Initial
PCR analysis will give an indication as to the segment in which
integration is most likely to have occurred, provided only integrated HPV
is present in the sample and anchor-PCR analysis would be carried out on
these segments only. However, if episomal DNA is present in the sample,
anchor-PCR would have to be carried out for each segment (A-H) starting
with the most likely sites for integration that is E2, El and L2.
Template DNA would be digested with an enzyme which cuts within the
segment adjacent to the segment of interest. For example if investigating
the possibility of integration within segment D, (which covers El and E2
ORFs) template DNA would be cut within segments E or C (using PstI or
Haell respectively). The 3' ends of the DNA would then be tailed with
dATP. Segment D primer 1 (p-l-spec) would be used if cutting in E (with
PstI). Alternatively, segment D primer 2 (p-2-spec) would be used if
cutting in C (with HaeII)(figure 6.1). As restriction enzymes will cut at
known sites within episomal DNA, if only episomes are present, gel
electrophoresis of amplified products will show fragments of known
predicted lengths. In contrast, if integrated DNA is present then amplified
fragments will be of different unknown lengths depending on the cutting
site in adjacent host DNA (figure 6.3). Southern blot analysis of
amplified products using HPV type specific probes could then be used to
confirm which of the fragments contain HPV DNA.
The use of the A-PCR based assay offers the opportunity to gather direct
evidence of viral integration via amplification of viral-host DNA
junctions which could be subsequently cloned and sequenced if desired,
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Figure 6.3
Schematic representation of A-PCR assay for integration within the HPV
16 segment D (El, E2 genes). PstI will cut episomal HPV DNA at a
known site and genomic DNA adjacent to the integrated HPV genome at
an unknown site. A-PCR with p-l-spec and p-T-adapt will generate a
product of known length with episomal DNA and a product of unknown
length with integrated HPV DNA. That this product contains HPV
sequences can be confirmed by Southern blotting.
episomal
p-1-spec p-1-spec
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for example, for investigation of host integration sites.
6.2.3 Primer Design
The entire HPV 16 genome was searched for eight suitable evenly spaced
sites with sixteen PCR primer sequences to be used both in the initial
PCR analyses and also with adapter and hybrid primers in the subsequent
anchor-PCR analyses. Non-specific amplification can be minimised if all
the primers in a particular reaction have similar melting temperatures.
Thus HPV specific primers were chosen which had a similar length and
GC content to the adapter primer. HPV specific primers were between
21 and 27 bases in length and had between 33% and 56% GC content,
whereas the adapter primer was 22 bases long and had a GC content of
54%. All primers were checked for any significant secondary structure as
predicted by the UW programs FOLD and SQUIGGLES and the program
FIND was used to exclude the possibility of exact or related (with up to 5
mismatches) primer sequences occurring elsewhere within the same or
other HPV types. The "unique" sequence chosen for the adapter primer
was an extended version of an adapter sequence described by Frohman
(1990) for use in a PCR protocol for rapid amplification of cDNA ends
(RACE) on which this A-PCR method is based. Sequences chosen for
HPV type specific primers and adapter primer are shown in table 6.4.
6.2.4 Optimization of the conditions for Initial PCR analysis
The standard PCR assay was optimized for each of the HPV type specific
primer pairs using the cloned HPV16d plasmid DNA (figure 6.5). This
plasmid contains a head to tail tandem duplication of prototype HPV 16
cloned into pBR322 at the BamHI site . The use of this plasmid allowed
the amplification of all segments (A-H) of the HPV 16 genome including
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Table 6.4
Nucleotide sequence (5' to 3') of the pairs of primers for segments A-H of
HPV 16, their position within the viral genome according to the EMBL
database nomenclature, length of amplified product and the open reading
frames covered by each segment.





A 1 CAT TAT GTG CTG CCA TAT CTA CTT GAG 6664-6690
933 L1. URR
A 2 QAA TGG TTG QCA AGC AGT GCA GG 7574-7596
B 1 CCT GCA CTG CTT GCC AAC CAT TC 7574-7596 1 133 URR. E6, E7
B 2 CTT CCA AAG TAC GAA TGT CTA CGT G 778-802
C 1 CAC GTA GAC ATT CGT ACT TTG GAA G 778-802 1 127 E7, E1
C 2 GTT GTA ATA CTG TTT GTC TTT GTA TCC 1879-1905
D 1 GG A TAC AAA G AC AAA CAG TAT TAC AAC 1879-1905 1013 E1, E2
D 2 GCC TTG TAA TAA ATA GCA CAT TCT AG 2866-2891
E 1 CTA GAA TGT GCT ATT TAT TAC AAG GC 2866-2891 978 E2
E 2 CAT AAA TCC AGT AG A CAC TGT 3823-3843
F 1 ACA GTG TCT ACT GG A TTT ATG 3823-3843
819 E2, E5. L2
F 2 GTA ATA CTA A AT CCT GAT ACA TCT G 4617-4641
G 1 GAT ACT GGG ACA GG A GGC AAG TAG AC 4617-4641
1084 L2
G 2 CAA CCT TAG ATA CTG GG A CAG GAG GCA 5674-5700
H 1 GTC TAC TTG CCT CCT GTC CCA GTA TC 5667-5692
1024 L2, L1
H 2 CTG AAG TAG ATA TGG CAG CAC ATA ATG 5667-5692
ADAPTER GAC TCG AGT CGA CAT CGT ATG C
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Figure 6.5
Diagram of the HPV 16d plasmid which contains two tandem copies of
HPV 16 cloned into pBR322 at the BamHI site.
pBR322
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segment H which cover the BamHI site in the LI ORF used to clone a
single copy of the HPV 16 genome. The annealing temperatures were
optimized by setting up separate PCR reactions and increasing Ta by
increments of 2°C starting at 50°C until yield of desired amplified
product was optimised 1. A Ta of 56°C could be used successfully with
all primer pairs (figure 6.6A).
The primary standard PCR assay was applied successfully to extracted
DNA from two cases of cervical carcinoma processed in paraffin wax.
For both cases all eight reactions generated fragments of predicted length
indicating the presence of episomal HPV DNA (figure 6.6B).
6.2.5 Selection of Restriction Enzyme Sites
The UW program MAPPLOT was used to search the entire HPV genome
for suitable restriction sites for use in the anchor-PCR analysis. To be of
use restriction enzymes had to fit several criteria: to create a 3' overhang
to maximise the efficiency of subsequent TdT tailing; to have at most a
six base, but preferably a four base, recognition sequence in order that
host DNA is likely to be cut at frequent enough intervals to allow PCR
amplification of products less than 2.5kb - the empirical maximum for
efficient PCR (Saiki, 1989); to cut within one segment (A-H), but neither
of the two adjacent segments. Several possible sites were found for each
segment the best of which are shown in figure 6.1.
6.3 Results
The anchor PCR method including restriction enzyme digestion and TdT
tailing was validated using HPV 16 DNA cloned into pBR322 at the
BamHI site (pHPV16) to mimic integration within the viral LI gene
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Figure 6.6
Agarose gel electrophoresis of amplified DNA from (A) cloned HPV 16
plasmid DNA and (B) a case of adenocarcinoma using primer pairs for
HPV 16 segments A (a;length 933bp), H (b;1024bp), G (c;1084), F
(d;819bp), E (e;978bp), D (f;1013bp), C (g;1127bp) and B (h;1133bp).
Both (A) and (B) include a lkb ladder marker track (M).
A) Mabcdefgh
B) Ma bcde fgh
122
(segment H).
Firstly, plasmid DNA was linearised by digestion with restriction enzyme
Aatn which cuts pBR322 once at position 4290 but will not cut HPV
DNA, generating one fragment approximately 12kb in length upon
agarose gel electrophoresis (figure 6.7). The 3'end labelling with TdT
was then validated using Aatn restricted pHPV16 DNA and p32-iabelled
dATP. Tailed fragments were electrophoresed on agarose gels and
successful 3' poly A tailing confirmed by autoradiography (figure 6.8)
Tailed AatH digested pHPV16 DNA and HPV specific primer (p-l-spec)
for segment H were used to develop the anchor-PCR protocol. The RACE
protocol (Frohman, 1990) which is very similar in principle to the anchor-
PCR method was used as a starting point. However, the use of this
method did not result in the amplification of a specified fragment of
predicted length. Multiple modifications were made to the method. These
involved increasing denaturation, primer annealing and extension
temperatures, reducing dNTP concentration, omitting DMSO, decreasing
hybrid primer (p-T-adapt) concentration with respect to adapter (p-adapt)
and specific (p-spec) primers. The protocol as described in Chapter 2
resulted in successful amplification of the specified fragment (consistent
with the predicted length of 1028bp) detected by agarose gel
electrophoresis (figure 6.9).
6.4 Discussion
A PCR based assay was designed for the determination of the physical
state of HPV DNA in small clinical samples such as those from punch
biopsies of CIN. The first stage of the assay was designed to detect the
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Figure 6.7
Agarose gel electrophoresis of the restriction enzyme digest of cloned
HPV 16 plasmid DNA using Aatll. A single fragment, 12kb in length is
generated (b, c; in duplicate). Included are an uncut HPV 16 plasmid
DNA track (a) and a lkb ladder marker track (M).
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Figure 6.8
Autoradiograph of Aatll restricted HPV 16 plasmid DNA, 3' poly A
tailed with [P32] labelled dATP (in duplicate; a, b).
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Figure 6.9
Agarose gel electrophoresis of cloned HPV 16 plasmid DNA restricted
with Aatll, 3' poly A tailed and amplified by A-PCR using p-spec-1 for
segment H (in triplicate; a, b, c). The size of the fragment generated is
consistent with the predicted length of 1028bp (from p-spec-1 site for
segment H in HPV 16 to the Aatll site in pBR322. Included is a lkb
ladder marker track (M).
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presence of monomeric and irregular multimeric episomes and also to
indicate possible presence of integrated HPV DNA if no episomes were
present. The subsequent A-PCR stage of the assay was designed to
detect the presence of integrated HPV DNA.
The first stage of the assay has been successfully applied to cloned HPV
plasmid DNA and to clinical samples in the form of DNA extracted from
paraffin blocks of two cervical carcinomas. The absence of ghost bands
generated in this assay when applied to clinical samples is indicative of
its high specificity which could be attributed to the primer design
(primers were of at least 21 bases in length and had a %GC content of
33%-56%) which allowed the use of high annealing temperatures .
The high specificity of the HPV primers was particularly important to the
A-PCR analyses where the second primer is always the non-specific
oligo T-adapter hybrid (p-T-adapt). In order to maximise further the
specificity of the A-PCR assay an adapter primer was designed which
was similar to that described by Frohman for the RACE protocol with the
addition of 6 bases to the 3' end which allowed the use of higher
annealing temperatures. Also taken into account was the nucleotide used
in the tailing reaction; dC and dG were avoided as homopolymers of
these nucleotides bind with a much higher affinity than those of dA or dT
and therefore much shorter stretches of dCs or dGs than dAs or dTs are
required in the template DNA sequence for non-specific binding of the
complementary homopolymer-adapter hybrid primer. In order to improve
the efficiency of the tailing reaction from 20% to up to 90%, enzymes
were used which cut to give a 3' overhang, as opposed to a 5' overhang or
blunt ends.
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The A-PCR secondary step of the assay was successfully applied to
cloned HPV 16 plasmid DNA. However, it is likely that the method
described in Chapter 3 would have to be optimized and refined for use on
clinical samples. Frozen sections would be preferable to paraffin wax
processed tissue as a template source. It is possible that the application
of the A-PCR method to DNA extracted from paraffin wax embedded
tissue may prove problematic. Several investigators have reported
problems with certain restriction enzymes inefficiently digesting DNA
from tissue processed in this way. Such DNA preparations may not be in
a condition to allow PCR amplification over a distance greater than lkb
due to fixation and extraction procedures (Wright and Manos, 1990).
Once optimized for use on frozen sections of punch biopsies this assay
could offer several advantages over other approaches. The use of a PCR
based assay means that only very small amounts of DNA are required
and thus the method could be applied to small clinical samples. The
approach described here should be less time consuming than those
requiring Southern blotting and two-dimensional gel electrophoresis. The
A-PCR amplification of integrated HPV DNA would allow the further
analysis of viral-host DNA junctions through cloning and sequencing
providing direct evidence for integration of HPV into the host genome
and permitting investigation of possible preferred host sequences for viral
integration. Finally, this assay could offer information about the region of
the HPV genome disrupted during integration. Such information could be
valuable in the study of possible effects of integration on viral gene
expression. Finally, this method could be used to survey large numbers
of cases of CIN 2, CIN 3, localised regions of microinvasive carcinoma
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and established invasive carcinoma, to generate accurate data on the
frequency of HPV integration in these lesions which could be used to





The prevalence of HPV DNA in normal control samples has been a
subject of debate for some years. Widely differing prevalences have been
reported and both the source of controls and the detection methods used
have been suggested as possible reasons for the discrepancies (Munoz et
al., 1988). Another additional explanation for the variation in HPV
prevalence is highlighted in a study by Schneider et al (1992) where the
repeated evaluation of HPV 16 status in cervical swabs from young
women with a history of normal Papanicolaou smears revealed temporal
fluctuation in individual HPV positivity. Smears from 21 women were
analyzed for HPV DNA at intervals of five weeks for one year using
PCR. Prevalence estimates per visit varied between 14.3% and 33.3%.
The cumulative prevalence was 66.7% as fourteen women were positive
at least once. It should also be bome in mind that negative control
samples are usually taken from one region of the transformation zone and
it is possible that repeated sampling of different regions around the
transformation zone may influence HPV prevalence rates.
In this study, no HPV DNA was found in any of the normal control
samples. This result should be interpreted with caution. It does not
suggest that there are no cases of HPV infection in the normal population
only that the prevalence of HPV infection in the normal population is
likely to be lower than recent studies have indicated (Young et al., 1989).
It is expected that the application of this detection method to further
control samples obtained at forensic autopsy would produce HPV
prevalence values similar to those of a recent study (3.5%) where
controls were selected on a random basis (Van de Brule et al., 1991).
The majority of studies investigating HPV prevalence have chosen
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controls designed to be representative of the general population. The
question of whether controls should instead reflect a population exposed
to the same risk factors as the cases with abnormal cytology has seldom
been addressed. Such a study would require a control group matched to
the test group (those with CIN and cervical carcinoma) for factors such as
age, smoking and sexual history, including age at first intercourse and
number of sexual partners.
This study was designed to provide accurate data on HPV prevalence for
each stage of the CIN-cancer sequence so as to determine the stages in
the sequence at which HPV may make important contributions. The
results demonstrate a prevalence jump of 25% to 60% from CIN 1 to
CIN 2/3 that can be interpreted in several ways. It is possible that CIN 1
may be induced by factors other than HPV infection, and thus may not
always represent a precursor stage to invasive cervical cancer.
Furthermore, in the CIN-cancer sequence HPV 16/18 infection may be
responsible for progression from CIN 1 to CIN 2/3 or possibly from
normal tissue directly to CIN 2/3 (figure 7.1).
Anderson et al (1991) have assessed the current system of nomenclature
for cervical epithelial abnormalities. Under the present system, diagnostic
consistency at the less severe end of the spectrum is appreciably worse
than at the severe end (Ismail et al., 1989). Epithelial changes which do
not quite amount to CIN 1 but are not normal may be currently
categorised as CIN 1. Anderson et al (1991) recommended the
introduction of a new category of epithelial abnormality to encompass
those lesions in which a diagnosis of CIN cannot be made with certainty.
It is possible that some of the CIN 1 lesions used in this study may fall
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Figure 7.1
HPV infection may, in the majority of cases (*), provoke conversion to
CIN 2/3 directly from normal tissue by-passing a stable CIN 1 stage, or
conversion from CIN 1 to CIN 2/3. Progression to invasive carcinoma
may involve integration of HPV DNA into the host genome, oncogene









into the proposed new category but these are likely to represent only a
small proportion of the cases.
It is possible that HPV types other than those investigated in this assay
may be responsible for inducing some CIN lesions. Lorincz et al (1987)
investigated HPV prevalence in CIN and cervical carcinomas using
Southern blotting. Although this method could detect a wide range of
HPV types, only HPV 6/11, 16, 18 and 31 were characterized. In CIN 1
lesions they found a 29% prevalence rate for HPV types 6, 11, 16 and 18
as compared with an overall HPV prevalence of 44%. HPV types of low
oncogenic potential (analogous with HPV 6 and 11) may be present with
increasing frequency toward the less severe end of the CIN continuum.
The results of this study support a role for HPV 16 and HPV 18 in
neoplastic progression. These two types were found in 80% of all
carcinomas. The remaining 20% may contain HPV types other than those
investigated in this study or be genuinely unrelated to HPV infection.
Clonal p53 mutations have been found in some HPV- negative cervical
carcinomas (Crook et al., 1992). It was suggested that somatic mutation
of the p53 gene mediates loss of p53 function in the absence HPV E6.
This may explain the apparently worse prognosis of HPV-negative
cervical cancers. However, the correlation is not absolute inasmuch as
there are HPV-positive cervical carcinomas which have mutated p53 and
HPV- negative cervical carcinomas which do not (Fujita et al., personal
communication).
There appears to be a relative tropism of HPV 18 for cervical
adenocarcinomas which have a poorer prognosis than squamous
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carcinomas. This is analogous to the situation described by Stoler et al
(1991) for HPV tropism in the clinically aggressive small- cell
neuroendocrine carcinomas of the cervix: HPV 18 was found in 78% of
18 of these carcinomas whereas HPV 16 was present in 2 (11%) and 2
cases contained neither type.
In this study, HPV 18 was detected in a much lower percentage of CIN
(8%) than squamous carcinoma (23%). This pattern was different from
that of HPV 16 which was found in in 38% of CIN lesions and 58% of
squamous carcinomas. These prevalence data for precursor lesions and
cancers may be expressed as a single index, for purposes of comparison
of viral types, by the calculation of Cancer/CIN ratios. HPV 16 had a
cancer/CIN ratio of 1.5 and HPV 18 ratio of 2.9, suggesting that HPV 18
is associated with a higher rate or risk of transition to cancer. Such ratios
are influenced by variations in both numerator and denominator, and
small changes in either may result in larger changes in the overall ratio,
particularly if the data set is small. Due to the limited number of CIN
lesions and carcinomas used in this study, the Cancer/CIN ratios must be
interpreted with caution. Ideally, calculation of such ratios would be used
to analyze results from a much larger data set. Such a data set is unlikely
to be available to many researchers and the differences in individual
detection assays makes the concept of a cumulative data set impractical.
Taking these qualifications into account, it appears that HPV 18 was
found to associate with a more advanced cervical neoplasia than HPV 16.
These results are strengthened by several reports of an association of
HPV 18 with a more aggressive or rapidly progressive type of carcinoma.
Walker et al (1989) reported a significantly higher recurrence rate
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associated with HPV 18- containing carcinomas as compared to those
with HPV 16, irrespective of tumour grade or histological type.
Furthermore, patients with HPV 18 containing tumours were more likely
to give a history of recent normal Papanicolaou smears than those whose
tumours contained HPV 16. Kurman et al (1988) found HPV 18 in a
much higher percentage of cervical carcinomas (22%) than in CIN lesions
(3%) compared to the prevalence of HPV 16 in 41% of cancers and 37%
of CIN lesions. Similarly, a recent study by Lorincz et al (1992) found
HPV 18, 45 and 56 in 27% of 153 cancers but only 6.5% of 261 high
grade CIN lesions. HPV 16 was found in 47% of both high grade CINs
and cancers. Although the possibility exists that HPV 18 associated
cancers may evolve by a different pathway than via CIN, there are
important clinical implications of a possible subset of lesions with a
capacity for rapid progression.
The assay used in this study was designed specifically to look for HPV
types of known oncogenic potential in cervical lesions and carcinomas.
Until recently there was little evidence about the oncogenic potential of
HPV types other than HPVs 6, 11, 16 and 18 and to a lesser degree types
31, 33 and 35. Prospective studies have now been conducted in order to
establish the relationship between particular HPV types and cervical
neoplasia (Lorincz et al., 1992). Graphic analysis of HPV prevalence
ratios at specific points in the diagnostic spectrum defined four risk
categories: (1) low risk (HPVs 6/11, 42, 43 and 44); (2) intermediate risk
(HPVs 31, 33, 35, 51, 52 and 58); (3) high risk/HPV 16; and (4) high
risk/HPV 18 (HPVs 18, 45, and 56). Particularly concerning, in view of
the proposed propensity of HPV 18 lesions for rapid progression, are the
high risk/HPV 18- related types (HPVs 45 and 56). With this in mind, a
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useful continuation of the present study would be type-specific PCR
detection of some of the less common genital HPV types (in particular
high risk HPV 18-related types 45 and 56 and intermediate risk HPV
types 31, 33, 51, 52 and 58) in different stages of cervical neoplasia. As
in the present study, type specific primers would be preferable to
consensus primers as the latter may fail to detect all HPV types within a
lesion as a result of preferential amplification of the type with a higher
concentration of viral DNA.
While HPV types 16 or 18 may be involved in progression to high grade
CIN, there are cases which regress and some which persist. Therefore,
this thesis looked at two further events which may contribute to the
development of invasive carcinoma - URR alterations and viral
integration.
PCR assays were designed to look specifically for small sequence
alterations in the URRs of HPV 16 and 18 found in cervical lesions. The
results of this study suggest that viral variants, such as those previously
described, are likely to be rare, although it is noted that regional
variations may exist. It is unlikely therefore that viral variants with large
scale URR alterations contribute to a large proportion of cervical cancers.
A study by Chan et al (1992) has shown that by far the most common
sequence alteration in the URR is the point mutation. Such small changes
in non-conserved and non-protein-coding sequences are unlikely to be of
great functional significance. Detection of point mutations could be
achieved by sequencing, although this would be both laborious and time
consuming. PCR-single-strand conformational polymorphism (PCR-
SSCP) has been developed for use in the rapid detection of point
mutations (Orita et al., 1989). This technique is based on the observation
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that in non-denaturing polyacrylamide gels, the electrophoretic mobility
of single-stranded nucleic acid depends on its sequence in addition to its
size. PCR-SSCP could be used for the detection of point mutations not
only in the URR but in other HPV genes. Point mutations in the HPV E7
gene have been shown to affect transformation, transactivation and
phosphorylation by the E7 protein (Storey et al, 1990a) and may influence
vims oncogenic potential in vivo. Similarly, mutations in the E6 gene
may affect E6 protein binding affinity to the p53 gene product or E2
mutations - the negative control of transcription.
Finally, PCR assays were designed to determine the physical state of
HPV DNA in cervical lesions. HPV DNA has been found to be integrated
into the host genome in the majority of cervical carcinomas and
carcinoma-derived cell lies. The stage in the CIN-cancer sequence at
which this event occurs is unclear but may be of importance in predicting
which lesions are likely to progress. The results of some studies have
suggested that integration occurs most commonly towards the more
severe end of the CIN spectrum (Pater et al., 1986; Cullen et al., 1991).
However, most studies have used a combination of Southern blotting and
2-dimensional electrophoresis for determination of physical state of HPV
DNA. Some concern has been expressed regarding the accuracy of these
techniques when applied to DNA extracted from small cervical biopsies
(Pater et al., 1986). It is possible that a single copy of integrated DNA
would not be detected due to the low concentration of DNA in some
samples.
Several investigators have now designed PCR based assays for the
determination of HPV physical state which obviate problems of low
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concentration of DNA in cervical biopsies associated with the Southern
blot approach. Das et al (1992) have used a PCR based assay as a
complement to Southern blotting and two dimensional electrophoresis.
With this method, the generation of a PCR amplified product using
primers sited in the HPV E2 gene indicates the presence of episomal HPV
DNA whereas, failure of PCR amplification is indicative of the presence
of integrated HPV DNA only. The value of this approach as an additional
complementary test is questionable as it does not allow for detection of
HPV genomes integrated within HPV genes other than E2, such as El or
LI and could not detect integrated HPV DNA in the presence of the
episomal form. A similar approach has been adopted by van den Brule et
al (personal communication) although four pairs of HPV primers were
employed for the individual PCR amplification of segments of the El, E2,
L2 and LI genes.
One possible approach to the determination of physical state would be to
use an adaptation of the whole genome PCR method (Kinzler and
Vogelstein, 1989). Until recently this was not feasible due to constraints
on the length of DNA fragment amplifiable by PCR. The recent
development of automated heating blocks which have shorter ramp times
is likely to extend the applicability of this approach.
In this study, PCR integration assays were designed for use on clinical
material. However unlike other PCR assays the problems associated with
both the possible integration of HPV DNA in genes other than E2 and the
presence of integrated HPV DNA in the presence of the episomal form
were taken into account. One potential problem of this assay may arise
where both episomal and integrated DNA are present in the same sample
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and episomal DNA predominates over integrated DNA at a ratio of
greater than 5:1 which may tend to direct preferential amplification of the
more concentrated target sequence.
The assay has been applied in its entirety to cloned HPV plasmid DNA,
used as a mimic of integrated HPV and is likely to require some
refinement for its application to clinical material. This assay represents a
considerable improvement on other methods for the determination of
physical state of HPV DNA. Once optimised, it may be used to clarify the
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